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ABSTRACT 
Type 1 diabetes (T1 D) is associated with hypoglycemia and premature 
autonomic disturbance (using heart rate variability [HRV]) - both which have been 
implicated in sudden death. This study examined the effect of a single bout of 
intermittent high-intensity exercise (IHE) on nocturnal HRV in ten hockey players with 
T1 D and ten teammates without T1.D. HRV and BG were analyzed from 12am-:-6am 
following hockey activity and low activity days. Hockey-type IHE on a cycle ergometer 
decreased BG by -1.9 ± 2.8 mmol/L, while an actual hockey game increased BG by 1.0 
± 3.2 mmol/L. One participant experienced nocturnal hypoglycemia after a hockey game 
(lasting 230 min). A significantly better nocturnal HRV profile (QTc, SDNN, pNN50, 
RMSSD) was observed following the low activity day compared to the days where IHE 
took place (p<0.05). There was no difference in HRV between T1 D and non-T1 D 
participants. This study documented the unique ability of a hockey game to increase BG 
in youth with T1 D. Furthermore, given that decreased HRV is commonly noted in youth 
with T1 D, this study suggests that the onset of autonomic hindrances can be delayed in 
highly-active individuals. 
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LITERATURE REVIEW 1 
1. Heart Rate Variability 
Heart rate variability (HRV), in its most basic interpretation, refers to the beat-to-
beat alterations in heart rate (1). While a seemingly straightforward concept, this 
method has been utilized for the effective diagnosis of early autonomic dysfunction 
- - - -
since the 1960's, and is sometimes referred to as the window into autonomic control of 
the heart (91 ). Since its first conception as a medical tool, HRV has been used to 
assess various health impairments. On a more direct scale, it measures sympathetic 
and parasympathetic neural innervation at the level of the heart (1 ). The accessibility 
and sensitivity of this measure, combined with its ability to function as a surrogate 
measure of cardiac autonomic function, has led to its continued use in the present day 
(2). 
The intrinsic heart rate (HR) generated by the sinoatrial node of the heart, without 
any neurohormonal input, is 80-100 beats per minute (bpm). However, it is well 
understood that a healthy individual has a resting HR between 60-80 bpm. This 
discrepancy is accounted for by the input of the parasympathetic nervous system (PNS) 
which decreases the HR, and the sympathetic nervous system (SNS) which increases 
the HR. At any given time, the HR is determined by the imbalance between 
parasympathetic and sympathetic innervation, which is constantly changing to meet 
bodily demands such as with stress or exercise. At rest, there is unevenness between 
the two branches, with the PNS dominating. With exercise, the sympathetic arm 
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dominates to increase the HR which helps to enhance blood flow to the working 
muscles. 
With a healthy autonomic nervous system (ANS) the continuous neural 
stimulation to the heart alters the contraction of the myocardium in a very minute, but 
significant manner, leading to greater HRV. On the contrary, an impaired ANS results in 
reduced HRV which is associated with a poorer prognosis for a wide range of clinical 
conditions (1, 3, 4, 5). As such, HRV can be used as an indicator of autonomic function, 
but also of heart health. 
1.1 HRV Assessment 
An electrocardiogram (EKG) is commonly composed to quantify HRV in a 
convenient and non-invasive manner. A Holter monitor is often used as a reliable tool 
for assessing HRV. This small monitor can be set up in various configurations, including 
3-, 5-, 7-, or 12-electrode placements (Appendix D). The electrodes are affixed to the 
anterior chest cavity and receive the electrical signals transmitted through the heart, 
which are then recorded on a memory card in the Holter monitor. This electrical profile 
can later be uploaded and converted for both power spectral density analysis and time 
domain analysis using the EKG tracing that is composed by the Holter monitor. In either 
method, the analyst must first scan the EKG tracing in order to exclude ectopic beats 
and artifact (1 ). After this point, the statistical parameters of the normal R-R intervals 
(NN intervals) can be derived in order to compute several time and frequency domain 
HRV indices (1 ). 
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1.2 Power Spectral Density Analysis (Frequency Domain Analysis) 
Power spectral density analysis involves decomposing the variance between RR 
intervals into underlying frequencies that fall between 0.003-0.40 Hertz (Hz) (1 ). These 
frequencies can be further segmented to identify PNS and/or SNS predominance. A 
frequency between 0.003-0.04 Hz is termed very low frequency (VLF) and is believed to 
represent the SNS innervation (6), although several studies suggest it is influenced 
primarily by humeral and hormonal factors (1). Activity between 0.04-0.15 Hz is termed 
the low frequency (LF) band, and is believed to indicate a combination of both the SNS 
and PNS branches (1 ). The high frequency (HF) band (0.15-0.40 Hz) is believed to 
reflect the PNS or vagal activity (1 ). HF is also known as a respiratory band because it 
correlates to the NN variations that are observed with respiration (1). All power spectral 
bands are calculated in squared milliseconds (ms2). Because the identified power in 
each frequency band is related to the total power, it is often recommended that power 
spectral bands be reported in normalized units (1 ). In this method, the low or high 
frequency power are expressed relative to the total power minus the very low frequency 
band (1). Utilizing this method, it becomes possible to infer that changes in low or high 
frequency power are reflective of a change in sympathovagal balance, and not just a 
mere change in the total signal strength (1 ). 
1.3 Time Domain Analysis 
The EKG tracings recorded by a Holter monitor can be partitioned into several 
meaningful variables. These values are the easiest to calculate (1 ), and include such 
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measures as QT length, QT length corrected for heart rate (QTc), R-R interval length, 
standard deviation of normal-to-normal intervals (SDNN), root mean square of 
successive differences (RMSSD), and percent of normal-to-normal intervals having a 
difference of >50 milliseconds (pNN50). Because these time domain indices reflect 
variance and variance increases over time, only HRV tracings of the same duration can 
be compared (1 ). In addition to these time domain measures, QT measurements are 
also informative. gT length represents t~e time required for a. single beat to occur, from 
the initiation of Sinoatrial node depolarization to the end of ventricular repolarization. 
The QTc length is a more accurate measure, as it corrects the QT length for the heart 
rate itself (7). Bazett's formula is commonly used to derive the QTc by dividing the 
measured QT interval by the square root of the preceding RR interval (QTc = QT /'1RR..) 
(7). It is understood in literature that an efficient heart with healthy neural connectivity 
should contract quickly, with QTc remaining below 0.440 ms (8). Furthermore, Schwartz 
et al (9) suggested a probability-based diagnostic test for diagnosing long QT 
syndrome. The test is out of 9, and a score of 3 or more indicates high probability of 
long QT syndrome. Considering QTc alone, a QTc of over 480 ms in males or females 
receives 3 points, from 460-4 70 receives 2 points, and a QTc of 450 ms in males is 1 
point. To reduce the likelihood of false positives, the QTc cut-off of >450 ms for boys or 
>460 ms for girls was used. Standard values published by the European Task Force (1) 
are included in Table 1. 
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Table 1. Summary of HRV indices and normal values of standard measures of 
HRV 
HRV Measure Meaning Expected 
Values 
*SDNN Overall HRV; higher is better 141±39 ms 
Standard Deviation of Normal-
to-Normal beats 
*RMSSD Index of vagal activity & 27±12 ms 
Root of the Mean of the Sum of parasympathetic activity at 
Squares of Diffe~ences between the h_eart; higher is better 
beats 
*PNNSO Alterations of vagal activity, n/a 
Percent of adjacent Normal-to- independent of circadian 
Normal beats that differ by >50 rhythms 
ms 
**VLF Sympathetic activity n/a 
Very Low Frequency 
**LF Combination of sympathetic 1170±416 ms2 
Low Frequency and parasympathetic activity 54±4 nu 
**HF Parasympathetic activity 975±203 ms2 
High Frequency 29±3 nu 
**TP Index of overall neural input 3466 ±1018 ms2 
Total Power to the heart 
**LF/HF Ratio Reflection of sympathetic-to- 1.5-2.0 
parasympathetic balance 
QT Duration of heart contraction, n/a 
Q to T interval length from depolarization to 
repolarization 
QTc Duration of heart contraction <0.440 ms 
Q to T interval length Corrected when corrected for heart rate; 
for heart rate healthy ANS function should 
allow the heart to contract 
quickly regardless of heart 
rate 
*Triangular Index Estimate of overall HRV; 37±15 
larger is better 
*taken over 24-hour recording, **taken over 5-minute recording 
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1.3.a) SDNN 
SDNN is often used as an estimate of overall HRV. Mathematically, SDNN is equal to 
the square root of the variance in NN intervals (1 ). The variance is equivalent to the total 
power of the spectral analysis. The actual value of SDNN depends on the length of the 
recording, with longer recording periods resulting in higher SDNN values. As a result, if 
comparing HRV results between or within individuals, it is imperative that the recording 
duration is identical. Typically, short-term (5-minute) recordings an·d 24-hour recordings· 
are used for the assessment of SDNN (1 ). This measurement is reported in 
milliseconds, with larger values reflecting a better HRV profile. 
1.3. b) RMSSD 
RMSSD is an estimate of the short-term components of HRV (1). This measure 
estimates HF variations in the HR, using short-term normal-to-normal beats. Because 
HF waves predominantly represent PNS tone, RMSSD is thought to estimate PNS 
regulation of the heart. It also provides an index of vagal activity. Higher values are 
favourable. 
1.3. c) pNN50 
pNN50 reflects alterations in autonomic function that are primarily vagally-mediated (1 ). 
This measurement is independent of circadian rhythms, and is often depicted as a 
percentage, with larger values being favourable. 
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1. 3. d) Triangular Index 
The triangular index is an integral of the density distribution (ie number of NN intervals 
plotted on a histogram) divided by the maximum of the density distribution. This 
triangular index is said to be an estimate of overall HRV. 
1.4 HistQry of Heart Rate Var:-iability 
In the 1 ath century, Swiss scientist Albregth von Haller noted that a healthy heart beat 
was not regular, but rather displayed variations. While noted centuries ago, it was not 
until more recently that the clinical significance of this HRV was documented in the 
medical literature. In 1965, Hon & Lee noticed that alterations in beat-to-beat intervals 
preceded fetal distress, even before any change in HR could be detected (10). In 1977, 
Wolf et al showed an association of HRV and mortality, post myocardial infarction (11), 
and these findings have subsequently been confirmed (1, 3, 5, 12). Specifically, 
decreased HRV was noted in individuals recovering from a myocardial infarction, and 
those individuals with the greatest reduction in HRV also had the greatest risk for 
sudden death (13, 14, 15, 16). Linear methods such as time domain measures were 
most commonly used to assess HRV due to their simplicity, until Akselrod et al 
uncovered the abilities of power spectral analysis in 1981 (17). This new-found ability to 
quantitatively evaluate beat-to-beat cardiovascular control based on power spectral 
analysis of HR provided additional methods of assessing the same HRV measures. In 
1996, a task force came together to publlsh measurement standards for HRV. To date, 
research on HRV measures continues to evolve. 
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1.5 Heart Rate Variability and Chronic Exercise 
Healthy individuals typically have a high total power (TP) which represents greater 
overall ANS innervation (18), and a low LF/HF ratio due to the prop.ortionately larger 
PNS innervation to the heart. This low LF/HF ratio is exaggerated even more so during 
sleep. Important to note is the fact that a healthier HRV profile, reflected by HRV 
indices, is observed in those who partake in habitual physical activity. Previous studies 
(19, 20, 21) have·shown that measures of HRV tend to be better and higher in 
physically active compared to physically inactive, healthy individuals. 
While those with type one diabetes (T1 D) have lower HRV than those without, 
habitual physical activity has been implicated in increasing HRV in healthy children with 
initially low HRV (20, 22). The influence of physical activity level on autonomic function 
in T1 D was first reported by Chen et al (90). This report suggested that a higher 
physical activity level was synonymous with higher HRV in children with T1 D. It was 
also suggested by Chen and his colleagues that a decreased HRV is only present in 
children with T1 D (mean age 10 years) with a low level of physical activity participation, 
but not in those with moderate-to-high levels of physical activity participation (90). 
The experimental effects of exercise programs have proven themselves effective 
in improving HRV. While a moderate-intensity physical activity program may not 
improve HRV indices in those with definite or severe cardiac autonomic neuropathy 
(CAN), the outlook is more hopeful in diabetes patients with early involvement of CAN 
(34). Howorka et al (23) found that regular endurance train~ng for 12 weeks increased 
HRV in individuals who scored relatively low on their battery of cardiovascular reflex 
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tests, but that these training-induced changes disappeared 4-6 weeks following training 
withdrawal. In a study by K. Javorka et al (24), the effects of a sports camp on youth 
with T1 D who attended the camp either in the trained or untrained state was assessed. 
Trained individuals had significantly lower incidence of below-average HRV values at 
baseline. At the end of the camp stay, both groups experienced longer RR intervals 
(indicating a decreased resting HR) and increased HRV. Both groups also had an 
. increase in total spe<?tral power, largely du_e to an increased PN~ output. When the 
percent improvements in HRV measures from camp activities were compared between 
trained and untrained subgroups with T1 D, no differences were observed (24). This 
study provides an exemplary demonstration of the benefit that cumulative physical 
activity has on heart function, particularly due to its ability to increase parasympathetic 
activity and thus presumably heart efficiency as well. 
1.6 Heart Rate Variability and Acute Exercise 
It is widely accepted that improved physical fitness confers benefits to autonomic and 
heart function, as displayed by improved HRV measures. However it is important to also 
understand the acute effects that a single bout of exercise has on these systems. Pober 
(25) assessed the effects of a 1-hour cycling bout at moderate intensity, on HRV in 
healthy individuals. The results of the single bout of exercise on HRV were similar to 
published findings from long-term training; individuals experienced increased HF and 
decreased LF power at rest, indicating a shift toward increased PNS activity. This study 
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suggests that even a single bout of exercise may offer an acute cardioprotective effect, 
as reflected by the increased HF innervation. 
1. 7 Heart Rate Variability and Diabetes 
HRV is frequently used to identify autonomic dysfunction at the earliest, sub-clinical 
stages (2). A loog-term complication of type 1 and type 2 d.iabetes commonly includes 
progressive autonomic dysfunction which is characterized by early and widespread 
degeneration of small SNS and PNS fibers (26). Over time, this may progress to a 
diagnosable condition called diabetic autonomic neuropathy (DAN). Commonly-noted 
side effects of DAN include postural hypotension, persistent tachycardia, gastroparesis, 
gustatory sweating, and complications in the bladder and digestive tracts (1 ). 
The suggested etiologies behind DAN include neurovascular insufficiency, 
autoimmune damage, metabolic insult to nerve fibers, and neurohormonal growth factor 
deficiency (27). In a technical review by Vinik et al (27), it was reported that the 
metabolic disturbances associated with type 1 and type 2 diabetes cause pervasive 
damage of peripheral nerves and blood vessels. The abundant presence of the ANS 
throughout the body exposes virtually all organs to the manifestations of autonomic 
dysfunction. It is therefore suggested that a person diagnosed with either type 1 or type 
2 diabetes should be suspected of having at least subclinical disturbance of the ANS 
(27). A review by Ziegler et al demonstrated that the 5-year mortality rate in individuals 
diagnosed with diabetes is five times higher for those with diagnosed CAN than for 
those without (28). Therefore, the detection of these early disturbances, and an 
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understanding of the role of regular physical activity participation in ameliorating these 
disturbances are imperative in order to slow progression and subsequently better 
manage health complications (1 ). 
Both short- and long-term HRV methodologies have successfully been utilized to 
detect DAN (16, 29, 30-34). The most common finding in the HRV profiles of individuals 
with DAN is a reduced power in all spectral bands (33, 35). Also commonly cited is a 
leftward shift in the LF/HF ratio·, indicating proportionally larger sympathetic drive (34). 
This leftward shift represents parasympathetic withdrawal from the heart, which could 
presumably lead to an increased heart rate at rest and thus insufficiency and over-
working of the myocardium. 
Recently it has also been proposed that HRV be used as a predictor for type 2 
diabetes (T2D). In a study by Mercedes et al (36), an 8-year follow up of healthy adults 
in the Atherosclerosis Risk in Communities (ARIC) study revealed that individuals who 
were diagnosed with T2D had a significantly lower LF, lower SDNN, and higher resting 
HR at baseline (36). This relationship existed independent of other factors such as waist 
circumference and physical activity level. These results suggest that ANS dysfunction 
may contribute to the development of T2D in healthy adults, rather than being a mere 
consequence of hyperglycemia in diabetes as previously thought. 
1.8 Onset of HRV alterations in T1 D 
While it remains controversial as to when the first signs of reduced HRV can be 
detected in T1 D, it is clear that impairments are not reserved for those of upper age 
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ranges. Chen et al (90) found that in children aged 8-13, both HbA 1 c and T1 D duration 
were significant predictors of TP. This study also reported that individuals with a HbA 1 c 
above 8% and T1 D duration greater than 4.5 years had significantly lower HRV than 
other persons without T1 D. Similar findings were published by Kardelen et al, who 
concluded that in youth with T1D (mean age 12, mean HbA1c 9%) almost all time 
domain parameters were reduced (37). The same study showed that HRV indices 
reflected significan~ reductions in PNS a~tivity and trends of in~reased SNS tone a~ong 
youth with T1 D. In a study by Warwick et al on 130 persons with T1 D (38), a reduction 
of HRV could be detected as early as 1 year post-diagnosis, and this impairment 
worsened with increasing T1 D duration. Other studies have documented diminished 
PNS activity in persons with T1 D even before clinical symptoms of neuropathy were 
present (39- 41 ). 
The research literature is equivocal, as several studies have suggested an 
association with poor metabolic control (42-48), age (49), and longer diabetes duration 
(43-46, 48-50), while other studies report no such association to alterations in ANS as 
measured by HRV (47, 51-53). Progressing through puberty has been previously 
associated with peripheral and autonomic neuropathy in most (54, 55) but not all (44, 
45, 47, 48) studies. Studies by Massin et al (56) and Barkai and Kempler (57) 
emphasized the independent role of pubertal changes in the development of ANS 
disturbances, suggesting that reduced HRV could be observed at the onset of puberty. 
Massin's work (56) demonstrated that HRV indices were only significantly depressed in 
individuals aged ~11 years. It is generally suggested that early puberty is a critical 
period for the onset of ANS disturbances in T1 D. 
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1.9 Heart rate variability and Dead in Bed Syndrome 
A further issue that is implicated in ANS dysfunction in T1 D is hypoglycemia. A previous 
episode of severe hypoglycemia blunts the ANS responses and awareness to 
subsequent drops in blood sugar (58-60). Absence of hypoglycemic symptoms and 
awareness is part of the syndrome called hypoglycemia-associated autonomic failure 
(60, 61 ), and has been implicated in the dead in bed (DIB) syndrome. While DIB only 
accounts for 6-11 % of unexplained deaths in T1 D (62), its extreme· and elusive nature 
make it a pertinent area for research. In 1991, Tattersall and Gill reported 22 
unexplained deaths in young patients with T1 D (63). All of the deaths occurred at night, 
with the individuals being found the next morning in an undisturbed bed. This became 
the definition for DIB syndrome. In their study, the individuals were in seemingly good 
health the day before, however upon retrospective examination, many had recently 
experienced nocturnal hypoglycemic attacks. This study by Tattersall and Gill (62), 
along with many others (63-66), provide strong evidence that sudden death in youth 
with T1 D may be related to hypoglycemic-induced cardiac arrhythmias. Because · 
hypoglycemia rarely results in sudden death, it is believed that some other factors must 
predispose persons to this adverse event. As previously mentioned, autonomic 
neuropathy may impair the counter-regulatory response to hypoglycemia, thus it is 
hypothesized that dead in bed syndrome may be a consequence of both hypoglycemia 
and autonomic dysfunction that particularly impacts the heart. Additionally, there is 
evidence that reduced PNS activity contributes to cardiac electrical instability which 
could trigger ventricular dysrhythmias that could lead to sudden cardiac death (67). 
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During hypoglycemia, there is a notable elongation of the corrected QT interval 
(68). Hypoglycemia is also associated with increased plasma catecholamines and 
decreased serum potassium, both which are hypothesized to lead to QTc prolongation 
(69, 70). A follow-up study by Weston & Gill (71) looked at the relationship between 
nocturnal hypoglycemia and QTc intervals and found that not only was QTc elongation 
present with hypoglycemia, but the incidence of HR rhythm abnormalities was also 
signif~cantly greater. Elong~tion of the QTc inte~al on ECG tracings of persons with 
T1 D has been associated with sudden cardiac death when abnormal ANS function is 
also present (32, 72). Other research (73) suggests that hypoglycemia causes 
increased QTc and QT dispersion (QTd) in pre-pubescents and adults with T1 D, 
independent of ANS dysfunction. Prolonged QTc interval can trigger ventricular 
tachyarrhythmias, even in the absence ANS dysfunction (73). 
During sleep, a decrease in the LF/HF ratio is commonly observed (74), however 
in T1 D, nocturnal LF predominance has been reported (34). Nocturnal hypoglycemia 
further increases the LF/HF ratio, indicating even greater sympathetic-to-
parasympathetic imbalance (71 ). In a recent study on adults with T1 D by Koivikko et al 
(75), HF did not change during nocturnal hypoglycemia, while LF increased. There was 
a significant negative correlation between LF power and glucose concentration (75). 
More importantly, hypoglycemia and increased sympatho-vagal imbalance are 
associated with lengthened QTc - a further risk factor for ventricular dysrhythmia (71). 
This relationship is depicted in Figure 1, published by Weston and Gill, 1999 (71 ). 
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Figure 1: Proposed explanation of the 'dead in bed syndrome' in T1 D. Fatal 
ventricular arrhythmias may result from early autonomic neuropathy combined 
with hypoglycemia, and triggered by QT abnormalities. 
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2. Type 1 Diabetes Mellitus 
Of the estimated 347 million cases of diabetes worldwide (76), the Canadian Diabetes 
Association suggests that 10% are believed to have T1 D (77). Although less prevalent 
than T2D, T1 D is associated with many long-term complications, as it is most commonly 
diagnosed in children and young adults and therefore requires life-long management. 
Currently, Canada has one of the highest reported incidence rates of T1 D in youth 
under the age of 14, in the world (76). The incidence is increasing particularly in children 
under the age of 5 (78). 
T1 D is characterized as an autoimmune disease affecting the ability of the 
pancreas to secrete insulin to stabilize blood sugar levels (77). As a result, the tissues 
of the body rely on the injection of synthetic insulin in order to uptake and utilize 
circulating sugars (77). Because this typically-closed-loop homeostatic system has to be 
controlled through external manipulation, maintaining healthy blood sugar 
concentrations becomes a daily challenge for individuals with T1 D. Without adequate 
insulin, these individuals experience elevated blood glucose (BG) levels called 
hyperglycemia. Slight hyperglycemia generally does not pose acute threats, and thus is 
often considered less problematic by persons with T1 D. Nonetheless, it is important to 
limit the time spent in hyperglycemia, as high BG levels are associated with cumulative 
and chronic complications in the long-term. Typically, priority is given to avoiding low 
blood sugar, or hypoglycemia, in T1 D due to the acute severe and life-threatening 
challenges that it can introduce. The primary challenge for individuals living with T1 D is 
to sustain a healthy BG range, between 4-7 mmol/L (euglycemia). While this is largely a 
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balancing act between dietary carbohydrate consumption and insulin intake, this 
relationship is also under the influence of circulating hormones which makes 
management increasingly difficult with activities such as exercise and psychological 
stressors. 
2.1. Type 1 Diabetes and Exercise 
On one hand, the vast benefits of physical activity participation for those with T1 D, 
including weight control, blood sugar control (79), and benefits on lipid profile (80, 81 ), 
make daily physical activity a compelling adjunct therapy. However, physical activity 
may also complicate the task of immediate blood sugar management, making it 
especially troubling for athletes with T1 D (82). As such, determining the most suitable 
strategy for managing T1 D with physical activity requires careful consideration of the 
type and intensity of physical activity to be performed. 
2. 1. a) Aerobic Exercise 
Moderate-intensity physical activity occurs at around 40-59% of maximal 
exercise capacity (V02 max) (83), or 50-70% of heart rate reserve (HRR) (84), with a 
heavy reliance on aerobic metabolic processes. Aerobic activities typically include 
steady-state, endurance activities such as jogging, swimming, and cycling (26). 
Moderate-intensity physical activity is accompanied by greater glucose uptake by the 
muscle, which leads to a drop in BG in persons with T1 D both during and after exercise 
(84). A common cause for this decrease is a relatively over-insulinized state in the 
body, resulting from insulin which, once injected in the body, remains in circulation for 
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several hours (82). As a result of the hyperinsulinemia, glucagon release is inhibited 
which therefore reduces hepatic glucose production (83, 84). Additionally, physical 
activity increases glucose transport out of circulation and into the working muscles due 
to the exercise-induced increase in insulin sensitivity. All of the above factors lead to an 
increased risk of hypoglycemia with exercise . 
. To prevent hypoglycemia with whole body, sustained, moderate-intensity 
activities, it may-be advised to reduce· insulin prior to the physical activity session·, or 
supplement with carbohydrates during the activity that exceeds 15-30 minutes (84). The 
prescription for carbohydrate supplementation depends on not only the duration and 
intensity of the physical activity being performed, but the individual's starting blood 
sugar as well. Another technique to prevent hypoglycemia with whole body, sustained, 
moderate-intensity activities is to include short, maximal sprints in the session to 
counter the fall in blood glucose levels (83). One study (83) reported that when 20 
minutes of easy pedalling on a cycle ergometer was performed in males with T1 D, 
blood glucose levels continuously dropped both during and following the physical 
activity session. When a 10-second cycling sprint was introduced at the end of the 20-
minute workout, the decline in BG was no longer apparent for 2 hours following the 
physical activity session. 
2. 1.b) High-Intensity Intermittent Training (HllT) 
HllT training incorporates short bursts of maximal or near-maximal effort that cannot be 
sustained for long periods of time, and thus are separated by periods of lower intensity 
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physical activity. High-intensity exercise occurs at 80-100% of V02 max (83), or 70-85% 
of HRR (84), resulting in a greater production of lactic acid and larger reliance upon the 
anaerobic system. Because of the different metabolic processes which dominate at 
different exercise intensities, physiological responses vary accordingly, thereby adding 
to the difficulty of BG management in T1 D. 
In particular, the short sprints found in many sporting activities and spontaneous 
play in children, require intermittent bouts of high-intensity exercise, or IHE (85). During 
this type of physical activity or exercise, large demands are placed upon the body in a 
short amount of time, which requires muscle glycogen to be broken down for fuel. 
Catecholamine-mediated glucose production from the liver causes an elevation in BG 
during this type of exercise (86). Upon cessation of exercise, the catecholamine-driven 
inhibition on insulin is removed, insulin levels rise, and glucose is shuttled into the 
muscle to replace glycogen stores. In T1 D, if there is insufficient circulating insulin at the 
onset of activity, an exercise bout can induce hyperglycemia. Furthermore, following 
exercise, it is difficult to know whether the GLUT4 transporters will sufficiently lower BG 
by replenishing glycogen stores, or whether an insulin bolus is needed to correct for the 
prevailing hyperglycemia. When individuals with T1 D undergo intermittent high-intensity 
exercise (IHE), BG levels fall less rapidly compared to moderate-intensity exercise, and 
remain more stable in the hour following exercise despite doing more total work with 
IHE (87). This is partly explained by muscle glycogen which is used as fuel instead of 
circulating BG. As a result, there is a greater need for carbohydrate consumption both 
30-60 minutes and 7-11 hours following exercise, when glycogen stores are being 
replenished (88). Failure to closely monitor BG trends after IHE may result in late-onset 
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hypoglycemia, which is particularly dangerous if experienced during nocturnal hours, 
while sleeping. 
2.2 T1 D and Hockey 
From a brief glance at rosters of ice hockey players, it becomes evident that T1 D does 
not limit individuals from reaching elite and competitive levels of this popular North 
American sport. As a result of its popularity among youth, well-rounded T1 D care calls 
for established recommendations for effective T1 D management with hockey. Such 
guidelines require efforts to study these individuals both observationally and 
experimentally, in both naturally-occurring and more tightly-controlled settings. 
One reason that specific research is needed for athletes of this sport is because 
of the unique nature of hockey. In a pertinent study by Montgomery (89), hockey was 
characterized by high intensity intermittent skating with quick alterations in velocity and 
duration, and frequent body contact. The typical professional player performs for 15 to 
20 minutes of a 60-minute game. Each shift lasts from 30 to 80 seconds with several 
minutes of recovery between shifts. The high-intensity bursts require muscular strength, 
power, and both anaerobic and anaerobic-aerobic endurance. On the other hand, the 
prolonged duration of the game and the need for quick recovery between shifts 
demands an efficient aerobic system. Peak heart rates during a shift on the ice exceed 
90% of HRmax with average on-ice values of about 85% of HRmax. As a result of the 
various metabolic systems at play during hockey, and the dynamic nature of the sport, 
general guidelines for sport participation for persons with T1 D require modification, 
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Despite both intra- and inter-individual differences with BG trends and physical 
activity participation, anecdotal reports of BG patterns with hockey activity display 
general trends. Individuals with T1 D commonly report an elevation in BG with hockey 
games, with optimal performance occurring at a BG level between 8-10 mmol/L. 
Unfortunately guidelines specific to hockey players with T1 D do not currently exist, as 
this is a largely un-researched area of T1 D management. Widely-practiced 
recomme~dations for BG mana~ement with general l_HE-type activities, su~h as hockey, 
are typically based on anecdotal reports, or strategies used for continuous "competitive 
activities" such as swimming and cycling (84). 
For insulin pump users, some guidelines pertaining IHE include removing the 
insulin pump or reducing basal rates by 50-70% on the day of the activity (84). Further 
game-related recommendations include reducing meal boluses by 25-50% if a game is 
scheduled within 2-3 hours of that meal, and consuming 15-30 grams of carbohydrate 
per hour of activity, depending on the individual's playing time and intensity (84). If a 
game occurs in the night time, it is recommended to reduce basal rates by 10-20% 
overnight following extensive play in the evening, and to consume a bedtime snack to 
prevent nighttime hypoglycemia (84). These are recommendations made by one 
diabetes handbook, but have not been widely disseminated to the T1 D population, 
perhaps because of a lack of scientific evidence behind them. 
Because of the complications that arise with dysglycemia, it seems absolutely 
paramount to closely monitor BG in order to optimize sport performance and mitigate 
the health complications that can arise from poorly controlled BG. Because of the 
unique nature of hockey activity compared to other exercises and sporting activities, it is 
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important that research be conducted on this specific group of athletes to provide· 
guidelines for future players. The current lack of research in this area leaves families of 
hockey players with T1 D to discover their own strategies through trial and error. It can 
be frustrating for the children with T1 D as well as their parents, and it can be dangerous 
if careful precautions are not taken to avoid extreme BG excursions. Additionally, 
mismanaged BG on the ice can prevent players from reaching their potential and can be 
. discouraging, which_ ultimately prematurely ends their participat_ion in hockey. With . 
documented research, information and guidelines can be made available to parents, 
coaches, fellow athletes, and physicians, and can therefore assist with T1 D 
management while encouraging continued participation in their chosen sport. 
Summary 
In sum, it is unknown what acute impact physical activity or exercise has on nocturnal 
HRV profile in individuals with T1 D. Although it is commonly agreed upon that habitual 
physical activity offers benefits to HRV profile, the acute effects of physical activity 
participation on subsequent, nocturnal HRV remain largely unknown. This is an 
important area of research for athletes with T1 D, who regularly participate in intense 
levels of physical activity. It has been published that overtraining leads to increased 
cardiac SNS tone during rest, as well as decreased overall HRV, signifying PNS or 
vagal withdrawal (41 ). Given the causal links between physical activity and night-time 
hypoglycemia, and between nocturnal hypoglycemia and worsened ANS function, this 
research aimed to assess whether a single bout of physicar activity may predispose 
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individuals with T1 D to worsened nocturnal HRV following the physical activity bout. If 
this is found to be the case, then it may help to explain why several reports of DIB have 
occurred in highly-active individuals (92, 93). 
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OBJECTIVES & HYPOTHESES 
1) To observe the naturally-occurring trends of blood glucose levels with hockey 
participation. 
2 
- While variances will occur between each participant, it will be interesting to 
note whether general trends are present during games, and in 24-hour 
recovery. Given the anecdotal reports of glycemic highs during games, we 
hypothesize that continuous glucose monitor tracings may reveal post-hockey 
hyperglycemia followed by an increased incidence of nocturnal glycemic lows. 
This could be due to over-correcting for the post-game high or due to 
insufficient carbohydrate consumption after the game. 
2) To assess the immediate effects of highly-intense physical activity on subsequent 
nocturnal autonomic function in youth with T1 D 
Because of the correlation between hypoglycemia and worsened HRV, we 
hypothesize that acute HRV may be worse in participants with T1 D following 
a hockey game, compared to their healthy controls. We predict that on a non-
exercise day, no differences will be seen between T1 D and non-T1 D 
participants, due to the cardioprotective effects of exercise which may result 
in a delayed onset of ANS disturbances in these highly-active athletes with 
T1D. 
3) To measure the relationship between nocturnal BG and ANS function 
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- We hypothesize that as has been previously published, periods of low BG will 
result in QTc elongation. We will further study the relationship between 
hypoglycemia, hyperglycemia, and ANS function by assessing other HRV 
parameters during hypoglycemia. 
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CONTRIBUTION OF THE AUTHORS 3 
This project was conceived and designed through collaborative efforts involving 
Dr. Riddell, Dr. Jamnik, and myself. Subject recruitment and scheduling for lab visits 
was primarily my responsibility. Fitness assessments on participants were conducted by 
me, with assistance from members of the human performance lab which included Dr. 
Jamnik. I directed the hockey-type lab exercise protocols which were carried out with 
the assistance of several members of the fitness lab. Main contributors to the 
completion of the hockey-type lab exercise protocols include myself, Dr. Jamnik, Dessi 
Zaharieva, Robbie Gumieniak, Chip Rowan, Justin Sanderson, and Deandra Fillipo. 
CGM insertion for participants was conducted by a qualified diabetes specialist -
in most cases, Dr. Riddell. I was responsible for uploading the CGM data and pooling 
the data into Excel sheets. I also conducted all of the statistical analyses and composed 
all of the tables and figures seen in this thesis. 
Northeast Monitoring received the original HRV file uploads and had a lab 
technician scan them for heart rate abnormalities. I learned how to run the software and 
ECG analyses myself, which allowed me to carefully scan through each of the 
participants' files and process the data using their software. I was blinded to the file 
name to protect from bias. 
Dr. Riddell is the principle investigator and co-supervisor of this project. Dr. 
Jamnik is also a co-supervisor of this project. 
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METHODS 4 
Ethics 
This project was reviewed and approved by the Human Participants Review Sub-
committee at York University's Office of Research Ethics. 
Recruitment 
Endocrinologists and diabetes clinics in the Greater Toronto Area were contacted and 
supplied with recruitment flyers (Appendix A) for distribution at their clinics. Flyers were 
also posted in various arenas and hockey-centred fitness facilities through the Toronto 
area. Additional postings regarding the study were made online, through platforms such 
as Facebook and Twitter. Parents of youth who participated in a T1 D-focused sports 
camp were also contacted via email. This word-of-mouth recruitment was targeted at 
rep-level hockey players between the ages of 13-21 who had been diagnosed with T1 D 
at least 1 year prior. Upon initial contact with interested individuals, researchers inquired 
about pubertal level and age of diabetes diagnosis. A teammate for each individual was 
selected to function as a control participant. These individuals were chosen based on 
possessing similar attributes as our selected hockey players with T1 D, such as age, 
sex, height, weight, and fitness level. The control participants completed identical 
measures to those with T1 D, with the exception of the continuous glucose monitor and 
BG checks which were exclusively used for the persons with T1 D. 
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Screening Tools 
Based on parental or guardian report, individuals who had not yet commenced puberty 
were excluded from this study. Furthermore if the individual was newly diagnosed, 
played hockey at a non-competitive level, or played goalie, they were not included in the 
study. Finally, individuals with any diagnosed nervous system dysfunctions or 
retinopathy were excluded. 
Each study participant was required to complete a PAR-Q+ (Appendix B) and if 
necessary, ePAR-med-X questionnaire (www.eparmedx.com) in order to screen for any 
contraindications to completing vigorous exercise as required by this study protocol. 
Minor assent forms were sent to participants under the age of 16 (Appendix C), while 
parental consent forms were supplied to their parent or guardian (Appendix D). For 
participants over the age of 16, informed consent forms were supplied directly to the 
participants (Appendix E). All aforementioned forms were emailed to the appropriate 
individuals before visiting the laboratory, in order to provide them with sufficient time to 
read them and present any questions to the researchers. Forms were collected at the 
initial laboratory visit. 
Laboratory Measurements 
1. Anthropometric Data. Weight was measured using a digital scale (Seca Alpha, 
Germany) with no shoes and light clothing. Waist circumference (WC) was measured 
using the National Institute of Health (NIH) protocol; the measuring tape was placed on 
the skin at the level of the iliac crest. Body fat percentage was determined through 
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bioelectrical impedance analysis (BIA) instrument (Tanita Scale, model TBF-612, 
Arlington Heights, Ill). Skinfold measurements were taken using Harpenden fat calipers 
at standard sites; biceps, triceps, subscapula, iliac crest and medial calf, as per the 
Canadian Physical Activity, Fitness and Lifestyle Approach (94). Markings were made at 
the skinfold sites as well as one centimeter below, first for where the fold was made and 
the second for the placement of the jaws of the fat caliper. BMI was calculated by using 
~eight in kilograms di_vided by squared height in meters. 
2. Anaerobic Fitness. Individuals were required to have a BG level of between 5-15 
mmol/L in order to commence the protocols for anaerobic and aerobic fitness 
assessment. If individuals were below this threshold, one attempt was made to correct 
the low by administering 16 grams of carbohydrate (4 tablets of Dex4). A re-
measurement was taken 15 minutes and 30 minutes after, at which point if the low was 
corrected, testing could proceed. If on the other hand, individuals were above the 
threshold upon entry to the laboratory, participants were recommended to consume 
water and could choose to take insulin or simply wait 15-minutes, at which point another 
BG reading was taken. Provided participants were within the appropriate range 15-30 
minutes after their initial check, we proceeded with the testing measures. If individuals 
were not in the target BG range within that time span, the fitness testing was scheduled 
for another day. BG was checked with the individual's own hand-held device. 
Anaerobic fitness was assessed using a 30-second Wingate protocol (95) on a 
Monark Ergomedic 894E Peak cycle ergometer. A 5-minute warm-up was administered 
on a cycle ergometer, during which time the Wingate protocol was explained to the 
participant. Resistance was calculated at 7.5% of the individual's body mass. Individuals 
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were placed at a seat height such that at maximal leg extension, a 10-15 degree angle 
remained at the knee joint. Participants were instructed to keep seated while pedaling 
as fast and hard as they could for the duration of the 30-second test. They were given 
the verbal cues "faster, faster, go" to accelerate their pedaling speed prior to the load 
being dropped for the all-out sprint. These cues were given to ensure that the 
participants were pedaling at their maximal cadence prior to the resistance setting in. 
Qualified fitness professionals adminis~ered the test while ve_rbally encouraging th~ 
participant for its duration. The ergometers were connected to a Monark software 
program in order to continuously record the revolutions per minute (RPMs) and watts, 
which could later be used to determine peak power output and fatigue index. At the end 
of the 30 seconds, the resistance was removed and individuals remained on the cycle 
ergometer for a cool-down period. Following this, participants lay supine for a 30-minute 
recovery period, while active stretching and BG checks took place. 
3. Aerobic Fitness. Following the 30-minute rest period, individuals participated in an 
incremental to maximum aerobic fitness test (V02max) provided their BG values were 
fairly stable and above 5 mmol/L. As per the Canadian Diabetes Association guidelines, 
16 grams of dextrose tablets were administered to individuals whose blood sugar values 
were below this level. Polar heart rate monitors were worn to obtain their peak exercise 
heart rate during the test. A modified Astrand and Pollock (1978) incremental-to-
maximum treadmill protocol was used for V02 max assessment. While walking on the 
treadmill, participants were familiarized with the general procedure and testing 
equipment. The protocol was designed based on incremental stages lasting 2 minutes 
in duration. The protocol for all individuals started at 3.5 mph at 0% incline, and then 
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proceeded to 5mph at 0% incline, and then 6mph at 0% incline. The stages that 
followed were tailored to individual biom~chanics; some participants stayed at a speed 
of 6mph while others ran at 6.5, 7, or 7.5 mph. The protocol proceeded such that 
increases in intensity occurred once every 2 minutes, and once a comfortable running 
speed between 6 and 7.5 mph was reached for a participant, the speed was kept 
constant. To increase intensity from that point on, the incline was increased by 2% 
every 2 m~nutes. Individuals we~e verbally motivated ~o run continuously fo~ as many 2-
minute stages as possible. When the participant was unable to complete a full 2-minute 
workload, the speed was brought down to a walk for 2 minutes which marked the 
beginning of the supramaximal workloads. For this portion, individuals would run at the 
same speed as their final workload from the continuous portion, with the incline 
increased 2% higher than the previous workload. These workloads lasted 2 minutes, 
and were separated by 2-minutes of walking on the treadmill. 
Open circuit spirometry, a form of indirect calorimetry, was used during the 
V02max assessment. The details of the open circuit spirometry involved the participant 
inhaling air from the atmosphere and expiring air through a mouth-piece attached to a 
two-way valve (Ewald Koegal Co, San Antonio Texas), connected to a hose and then to 
a 120L Tissot gasometer (Warren E Collins LTD. Braintree, Massachusetts), while 
wearing a nose plug. The fractional concentration of expired oxygen (FE02) and carbon 
dioxide (FEC02), and volume of air expired were measured in the final 30 seconds of 
each workload. From several of these recorded measurements, oxygen consumption 
(V02) and carbon dioxide production (VC02) could be calculated for each incremental 
stage. Oxygen and carbon dioxide concentrations of the expired air were analyzed 
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through rapid response gas analyzers (Applied Electrochemistry, Model S-3A and CD-
3S, Sunnyvale, California). Rating of Perceived Exertion (RPE) and HR were collected 
at the end of each stage. The V02 max test continued until volitional fatigue, or until the 
qualified exercise professionals concluded that physiological measures indicated that 
the participant had reached their V02 max. 
Blood Glucose Monitoring 
All participants with T1 D were fitted with a blinded continuous glucose monitor (CGM; 
Medtronic iPro2). Sensors were injected in the upper buttock using an auto-injector, 
operated by qualified nurses or diabetes specialists. This sensor and iPro2 system 
allowed for continuous measurement of subcutaneous glucose concentration, taken 
every 5 minutes for up to 6 days. An adhesive patch was placed over the CGM to 
optimize comfort while participating in intense physical activity. Participants used their 
own glucometers to obtain BG measures a minimum of once every 8 hours, which 
would later act as calibration points for the respective CGM tracing. Participants were 
also provided with log sheets to record their meals, carbohydrate and insulin intake, and 
activities they partook in. Following completion of the study, CGMs were removed by 
the participant and collected by the researchers for upload and retrospective analysis. 
Nocturnal BG was regarded as the continuous period from midnight (OO:OOh) to 
6:00 AM (06:00h), and was isolated from the CGM for the nights following the lab 
exercise, low activity, and hockey game. These values were later pooled together and 
graphed to assess overall mean nocturnal BG trends and area under the curve following 
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the three collection days. As for the acute exercise bouts themselves, glucometer 
measurements were taken before and after completion of the hockey game and hockey-
type laboratory exercise protocol in order to determine general BG trends with the two 
types of bouts. 
Heart rate variability 
1. Technique. Two commonly-used and accepted methods of assessing ANS function 
are muscle sympathetic nerve activity (MSNA) and HRV. While MSNA is considered the 
gold standard, it is an invasive measure which solely measures SNS activity from the 
peroneal nerve (96). For these reasons, a Holter monitor was selected as the most 
appropriate method for assessing HRV, a surrogate measure of ANS function for this 
study. All efforts were made to ensure that a continuous time period of 12:00-6:00 AM 
was analyzed for all participants. In the event that an extended length of artifact took 
place within the 6-hour time period (lasting 30 minutes or more), the time analyzed was 
extended past 6:00 AM to account for this lost time. 
2. Data Collection. Similar to previous studies analyzing nocturnal HRV (97), HRV was 
analyzed from 12:00 am -6:00 am using a Holter Monitor (Northeast Monitoring, DR 
200 HIE) with a 5-lead configuration. These small monitors measured 8.6 cm long by 
6.0 cm wide and 2.0 cm deep, and were worn in a pouch that attached around the hip. 
The sample frequency was 180 samples per second. These non-invasive monitors were 
worn on 3 nights within a 5 day span, to record the acute effects of a single bout of 
strenuous physical activity on nocturnal HRV. One of the 3 nights followed a regular 
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season hockey game which was played in the preceding evening. A Polar heart rate 
monitor was worn by each participant during this game, to collect HR fluctuations and 
therefore ensure the intensity of the exercise bout. Another of the 3 nights was to follow 
a laboratory-exercise protocol which simulated a hockey game in a controlled setting. A 
final recording night followed a low-activity day where no exercise was performed. 
Participants were provided with a tight-fitting spandex shirt to wear over the 
Holter wires, which aided in the signal clarity picked up by the monitor. The monitor was 
kept in a pouch worn around the hip, and data was stored for each night on a formatted 
2 GB SD card. Participants and their guardians were instructed how to set up the 5-lead 
configuration so that they could set it up independently at home. An instructional sheet 
and diagram depicting the configuration was also provided to the participants, and is 
located in Appendix F. Participants were instructed to sleep from 11 :00 PM or earlier, 
until 6:00 AM or later, on the 3 recording nights. Individuals were also provided with a 
log-sheet (Appendix G) to record the activities they participated in during the day, any 
emotional stress experienced, the time they went to bed and woke up, and the time they 
started and ended the Holter monitor recording period. On the days where nocturnal 
HRV was to be recorded, participants were instructed to abstain from physical activities 
occurring outside of the design of the study. This included highly intense or high 
volumes of exercise, playing or practicing sports, and physically-demanding activities. If 
required by individual schools, participants were provided letters to request their 
exclusion from school physical activity classes. 
3. Data Analysis. Data stored on the SD cards were uploaded remotely and sent for 
EKG analysis by an external company (Northeast monitoring, Mississauga, ON). Data 
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from each card was initially scanned for artifact and heart rhythm abnormalities by a 
trained technician, during the nocturnal EKG tracings stored on the card. Any 
abnormalities or true artifact were classified ~s such and excluded from the analyses. 
Because time domain measures depend on the length of the recording period, if a 
distorted signal (artifact) lasted 30 minutes or longer, the end-time of the analysis was 
extended accordingly. 
Beat identific·ation and classificatio·n were then performed by the automated 
computer program designed for these Holter recorders (LX Analysis, version 5.3 version 
D). Each QRS complex was then scanned by an individual who was blinded to the 
identity of the HRV study participant file, to ensure the correct markings of each beat 
classification. Following that, LX Analysis applied various mathematical algorithms to 
the EKG strips to calculate time and spectral domain measures in 5-minute intervals. 
Reported time domain measures included SDNN, RMSSD, PNN50, and several others. 
Power spectral domain measures such as VLF, LF, HF, TP, and LFfTP and HFfTP 
ratios were also calculated by LX Analysis. Several geometric measurements were also 
calculated, and included the logarithmic index and triangular index. An additional 
software program was developed by the software technicians at Northeast monitoring to 
analyze QT and QTc. This program was adapted to provide such analyses by applying 
Bazett's formula on data from 3-leads rather than the usual 12. Because only 3 leads 
were utilized, QT dispersion measures could not be determined. Six-hour averages 
were calculated for all HRV indices by the software program for the 12am-6am 
timeframe, and these values were used for subsequent intra- and inter-individual 
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analyses. All HRV parameters were defined according to international standards of 
measurements (1 ). 
QTc was calculated using Bazett's formula (QTc = QT /.JM) (7). Prolonged QTc 
was identified using recent criteria suggesting that QTc of 0.450 In boys or 0.460 in girls 
revealed moderate risk of having long QT syndrome, QTc of 0.460-0.470 represented 
higher risk, and QTc of 0.480 represented almost definite diagnosis of prolonged QTc 
(98) 
4. Statistical Analysis. HRV parameters were first analyzed by calculating each 
individual's mean value from their 6-hour nocturnal recording, each of the 3 recording 
nights. Means were then combined to compare differences between males and females, 
between T1 D athletes (T1-a) and non-diabetic (control) athletes (Ctrl-a), and to 
compare values following the laboratory exercise protocol and after the hockey game, 
compared to after a low-activity day. HRV in exercise recovery was also assessed by 
collecting mean values from the 30-minute span, and comparing those values based on 
sex and T1 D status. Means with standard deviations were calculated for all HRV 
variables, and T-tests were conducted to assess differences between groups. 
Significance was set at p<0.05. 
Hockey-Type Exercise Protocol 
1. Design. Individuals wore a coded polar HR strap and receiver during a regular 
hockey game that they played. These values were later observed for recognition of HR 
fluctuations during hockey games. Each sustained increase in the HR was assumed to 
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indicate a hockey shift, and subsequently studied for duration and intensity, as indicated 
by their HR. Each prolonged dip in the HR was associated with a rest between shifts, 
and was also analyzed for duration and intensity. From several of these game HR 
recordings, a standardized protocol (Appendix H) was developed for use during a 
laboratory-exercise protocol which simulated a hockey game in a controlled setting. This 
protocol consisted of three 20-minute periods of IHE on the same Monark Ergomedic 
894E Pea_k cycle ergometer wh_ich was used during t~e Wingate test. The ~rgometers 
were hooked up to laptop computers which processed and recorded measures such as 
revolutions per minute (RPMs) and watt output. Each period was separated by a 10-
minute rest period. As per the standard written protocol, participants were verbally 
instructed when to accelerate and decelerate their pedaling frequency. Verbal cues 
consisted of "go" "whistle" and "bench." On "go," participants were to simulate the effort 
that they would exert during a hockey shift. "Whistle" indicated a stoppage in play, 
where the player was allowed to either pedal on the bike with no resistance, or sit 
stationary. The term "bench" indicated a prolonged break, similar to when a player 
would be off the ice and sitting on the bench. During this time, the participant was to rest 
on the cycle ergometer. Resistance was set at 70% of the individuals Wingate 
resistance, or 5.25% of their body mass. 
2. In practice. Individuals were instructed to treat the approach for the laboratory visit 
similar to what they would do for a regular hockey game. Most T1 D participants 
consumed a carbohydrate-heavy meal before their hockey game, and reduced their 
insulin intake or preferred to suspend their insulin pump during hockey activity. As such, 
the same procedures, based on individual preferences, were recommended for the 
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hockey-type exercise protocol. The protocol was designed to take place between 3:30 
and 4:30 PM; approximately 4 hours after their lunch was consumed. 
Prior to beginning this protocol, participants with T1 D were required have a BG 
level no lower than 5 mmol/L. If an individual was below this safety cutoff, one attempt 
was made to correct the low by administering 16 grams of carbohydrate (4 tablets of 
Dex4), or a self-chosen snack containing a similar amount of carbohydrate. A re-
measurement was taken 15 minutes and.30 minutes after, at which point if the low was 
corrected, the hockey-type lab exercise protocol could ensue. If participants entered the 
laboratory with a BG level above 15 mmol/L, they were advised to consume water and 
could choose to take insulin or simply wait 15-minutes, at which point another BG 
reading was taken. Provided participants were within the appropriate BG range 15-30 
minutes after their initial check, we proceeded with the hockey-type laboratory exercise 
protocol. If individuals were not within the safe BG range within the allotted time span, 
the lab exercise protocol was scheduled for another day. 
To begin the lab exercise session, all participants were weighed and fitted with a 
Polar heart rate strap and Fitmate V02 max system (Image Monitoring). Heart rate and 
percent of V02 max were continuously monitored and recorded, as well as ergometer 
RPMs and Watts. BG checks were performed using the participant's own hand-held 
device, a minimum of once every 20 minutes. This occurred during the 10-minute break 
between periods, while participants could get off the cycle ergometers and walk around 
to stretch their legs. Participants were also encouraged to check their BG any time they 
wished. If at any time a participant with T1 D had decreasing BG levels that were 
trending toward a potentially unsafe level, dextrose tablets were administered orally (16 
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grams of carbohydrate as per the Canadian Diabetes Association guidelines). 
Immediately following the completion of this exercise bout and a short cool-down period, 
a 5-lead Holter monitor was placed on each participant while they lay supine in a dark, 
quiet room for 30 minutes to assess post-exercise HRV. After the 30-minute period 
passed, the Holter monitor was removed. 
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RESULTS 5 
In total, 14 males and 6 females were recruited for participation in this study, half of 
whom had T1 D. Anthropometrics and fitness measurements are reported in Tables 2 
and 3, respectively. Of note, individuals ranged in age from 13-17 and had all reached 
puberty according to parental report. One individual had been diagnosed with T1 D less 
than the intended 1-year minimum, but was included. in the study as they had surpassed 
the honeymoon period. Six participants were using insulin infusion pumps while 4 were 
utilizing multiple daily injections. All individuals with T1 D had a control subject whom 
was matched in age, sex, and fitness level. 
Of the 20 participants, 19 played ice hockey; 4 at the A-level, 4 at the AA-level, 
and 12 at the AAA-level or higher. One participant in the T1 D group was a competitive 
lacrosse player and was included due to the similarity of lacrosse and hockey. This 
individual contributed HRV and CGM values from the laboratory exercise protocol and 
low activity day, but not from a game day. Their non-diabetic control also contributed 
HRV values from the laboratory exercise and low activity day, but not from a game. The 
remaining subjects participated in all 3 events included in the study design; laboratory 
exercise, low activity, and a hockey game. 
This study did not aim to control BG values with exercise, and as such, meals 
and insulin were not controlled. Participants with T1 D were free from disease 
complications, and were in fair to good metabolic control (mean glycosylated 
hemoglobin [HbA1c] 8.2 ± 0.7%) according to their last check-up by their physicians. 
Two individuals were participating in a drug trial at Sick Kids hospital, aimed at 
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preserving kidney function. The drugs administered by this study were an ACE inhibitor 
and a statin. While the individuals may have been receiving treatment or placebo at the 
time of this study, neither drug is believed to impact HRV. 
Table 2. Individual anthropometric measurements for participants. 
Sex Age Height Weight WC Skinfolds DD HbA1c 
(yrs) (cm) (ka) (cm) (mm) (yrs) 
T1-a1 F 13.8 158 53.8 71.0 53.8 12.0 8.1 
T1-a2 F 17.5 167 64.4 74.0 95.3 2.0 8.3 
T1-a3 M 14.5 167 58.7 74.0 57.7 10.0 8.0 
T1-a4 M 17.6 175 73.3 79.0 56.6 15.0 7.9 
T1-a5 F 14.0 157 64.1 74.0 102.7 10.8 8.3 
T1-a6 M 15.1 175 65.1 73.1 35.9 2.0 7.9 
T1-a7 M 13.5 171 67.7 77.0 2.2 9.2 
T1-a8 M 15.0 175 83.3 86.7 53.2 4.5 8.4 
T1-a9 M 16.0 187 98.3 83.0 1.8 8.9 
T1-a10 M 15.0 178 76.6 84.0 63.0 0.9 6.7 
T1-a 15.2 171 70.5 77.6 65.0 6.1 8.2 
Average 
Ctrl-a1 F 13.1 163 55.5 74.0 55.8 -- --
Ctrl-a2 F 17.2 170 57.3 73.0 49.9 -- --
Ctrl-a3 M 14.4 170 68.5 77.0 70.8 -- --
Ctrl-a4 M 17.9 174 75.6 83.0 62.4 -- --
Ctrl-a5 F 13.8 154 52.1 72.0 52.8 -- --
Ctrl-a6 M 15.8 173 61.3 71.0 33.5 -- --
Ctrl-a7 M 13.6 176 73.1 79.0 -- --
Ctrl-a8 M 15.0 184 84.8 89.0 39.2 -- --
Ctrl-a9 M 14.5 187 70.3 72.0 -- --
Ctrl-a10 M 15.2 167 71.4 83.0 53.2 -- --
Ctrl-a 15.0 171.8 67.0 77.0' 52.1 
Average 
T-Test p•0.44 p•0.66 p=0.33 pa:0.85 p•0'.17 
Ctrl-a represents the non-diabetic athletes with respective numbers that correspond to 
their matched participant with T1 D. 
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Table 3. Individual fitness-related measurements for participants. 
HR min HR max Hockey V02max Peak Fatigue 
level ml Power (%) 
02/kg/min watts 
T1-a1 67 202 AA 56.2 471.9 46.4 
T1-a2 57 209 A 51.8 567.0 39.3 
T1-a3 51 190 AAA 59.0 647.4 48.0 
T1-a4 51 192 Jr. A 49.8 735.3 51.7 
T1-a5 48 186 AA 43.3 460.0 43.1 
T1-a6 55 204 AAA 56.0 705.1 38.6 
T1-a7 50 202 AAA 56.9 786.9 50.1 
T1-a8 51 188 AAA 59.3 910.1 65.9 
. T1-a9 58 187 AAA 47.2 
T1-a10 54 197 A 58.9 747.4 39.0 
T1-a 54' 196 53.9 670.1 46.9 
Average 
Ctrl-a1 65 204 AA 52.7 484.8 38.1 
Ctrl-a2 59 201 A 54.8 528.5 33.8 
Ctrl-a3 52 193 AAA 63.3 770.9 54.5 
Ctrl-a4 44 194 AA 62.4 886.1 56.3 
Ctrl-a5 63 189 AA 46.5 487.0 39.0 
Ctrl-a6 43 203 AAA 53.0 772.3 56.7 
Ctrl-a7 50 195 AAA 64.1 860.5 52.3 
Ctrl-a8 53 195 AAA 61.1 1019.0 54.3 
Ctrl-a9 52 193 AAA 51.8 
Ctrl-a10 43 201 A 52.2 635.4 54.5 
Ctrl-a 52 197 56.2 716.1 . 48.8 
Average 
T-Test p•0 .. 49 p•0.51 ps0.21 ps:0.14 p•0.58 
Ctrl-a represents the non-diabetic athletes with respective numbers that correspond to 
their matched participant with T1 D. 
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Results: 
A paired-samples 2-tailed T-Test revealed that there were no differences between 
groups based on any of the group characteristics. T1-a group had slightly higher sum of 
5 skinfolds, indicating larger fat mass, however this trend was inconsistent between 
pairs, resulting in no statistical significance (p=0.17). Results from the fitness 
assessments revealed an overall mean V02 max of 55.0 ± 5.8 ml 02·kg-1·min-1 across 
all athlete participants (range 43.3-64.1 ). Results from the Wingate te·st revealed an 
average peak power output of 693.1 Watts·kg-1 across all athlete participants (range 
460-1019). Results are summarized previously in Table 2. 
Hockey-Type Laboratory Exercise Protocol 
Two participants had BG below the 5 mmol safety cut-off prior to starting the hockey-
type laboratory exercise protocol. They were either treated with 16 grams of dextrose or 
a self-supplied snack which was similar to what they would consume at a hockey game 
if they were low. For both individuals, the single attempt was successful in correcting the 
low BG and thus it was deemed safe to proceed with the protocol. 
All T1-a individuals attended the laboratory with their Ctrl-a teammate and completed 
the 20-minute protocol three times, representing three periods. Between the periods, 10 
minutes of rest allowed participants to walk around, while the T1-a group could also 
check their BG, and consume dextrose tablets if necessary. One T1-a individual who 
had been treated with carbohydrate prior to exercise initiation, needed dextrose 
supplementation during the protocol. The exercise protocol is included in Appendix F. 
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V02, HR, and watt recordings from a representative period are included in Figure 2. On 
average, on-shift heart rates ranged from 85-100 % of HRR, with V02 ranging from 85-
110% of max, as per their V02 max test results. Off-shift heart rates ranged from 60-
70% of HRR, while V02 ranged from 30-50% of max. 
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Figure 2. Relative heart rate, V02 and power output during one repetition of the 
hockey-type laboratory exercise protocol 
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Hockey Game 
Polar HR monitors with coded straps were worn by individuals during a regular season 
hockey game. Games ranged in length from 1 hour, to 1 hour and 15 minutes and 
occurred in the evening hours. All individuals' hockey games included 15-20 shifts, with 
HR continuously ranging from 185-205 while on the ice, to 130-140 bpm while on the 
bench between shifts. Peak HRs attained during games surpassed those seen in 
laboratory during the V02 max testing. All games included one 10-minute break for an 
ice resurfacing to take place. 
Blood Glucose 
Ten individuals with T1 D wore the provided CGM and complete data was available for 
eight of them. One sensor was unable to be successfully uploaded, while another 
sensor came out of a participant before study completion. As a result, CGM data was 
available for eight of nine participants' hockey games, eight of ten individuals' laboratory 
exercise bouts, and nine of ten low activity days. For the two individuals whose CGMs 
were not functioning for the laboratory exercise bout, pre and post glucometer 
recordings were used instead. Pre and post glucometer recordings were also utilized for 
the 1 individual whose CGM was not working for the hockey game. 
Pre- and post-activity BG changes from the laboratory exercise and hockey 
game sessions are included in Figures 3 and 4, respectively. Average starting BG for 
the laboratory exercise was 8.5 mmol/L, while average ending BG was 6.6 mmol/L, 
indicating a mean change of -1.9 mmol/L. Of the 10 individuals with T1 D who completed 
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the laboratory exercise, 7 saw a decrease in BG while 3 experienced an increase. 
Average starting BG for the hockey game was 11.0 mmol/L, while average ending BG 
was 12.0 mmol/L, indicating a mean BG increase of 1.0 mmol/L. Of the nine individuals 
who contributed BG data from a hockey game, seven experienced an increase in BG 
from the start to the finish of their game, while 2 saw a decrease. 
The inter-individual variations in nocturnal BG control (00:00h-06:00h) on each of 
the three nights can be viewed in figures Sa-c. Mean nocturnal CGM values were 
calculated across all participants, and the mean differences in BG control following a 
day where the lab exercise, no activity, or the hockey game took place, are found in 
figure 6. Area under the curve (AUC) analyses revealed that BG remained highest after 
lab exercise (4143 mmol·L-1·min-1), lower after a hockey game (3S63 mmol·L-1·min-1), 
and lowest after a low activity day (3496 mmol·L-1 ·min-1). BG on the lab exercise night 
decreased, on average, 1.7 mmol/L from midnight until 06:00 in the morning. The 
tightest control was shown after the hockey game, with average BG values going from 
9.3 mmol/L at midnight to 10.1 mmol/L at 06:00, displaying a 0.8 mM increase. BG on 
the low activity night experienced the greatest drop throughout the night, from 11.3 
mmol/L at midnight, to 8.3mmol/L at 06:00. Individual CGM tracings from the nocturnal 
periods following lab exercise, low activity, and the hockey games are displayed in 
figures Sa, Sb, and Sc, respectively. 
Of particular importance, retrospective CGM analysis revealed that one individual 
experienced prolonged nocturnal hypoglycemia following their hockey game, while 
having their HRV assessed. The CGM report from this night is included in Figure 7. 
Hypoglycemia onset was at 01 :40h in the morning, and persisted through sleep until 
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05:30h, for a total duration of 230 minutes. One additional participant had a hockey 
tournament during the time in which a CGM was being worn for the study. We pre-
selected one night to assess this individual's post-hockey nocturnal BG and HRV, 
based on playing only one game in the preceding day, and wearing the Holter monitor 
at night. During this evening, BG management was good, however on the two other 
nights after hockey games, the individual experienced hypoglycemia which is worth 
reporting. On one ~ight, the individual e~perienced 30 minute~ of hypoglycemia, 
whereas on another night, 180 minutes of hypoglycemia occurred. These values were 
not included in any of the analyses included in this study. 
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Figure 3. Absolute BG concentrations immediately before and after the hockey-
type lab exercise protocol, as reported by the CGM and validated by glucometer 
readings. 
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Figure 4. Absolute BG concentrations immediately before and after individuals' 
hockey games, as reported by the CGM and validated by glucometer readings. 
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Figure 5a. Continuous Glucose Monitor tracings taken from 8 participants during 
the nocturnal period (12:00AM - 6:00AM), following the hockey-type laboratory 
exercise protocol. 
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Figure Sb. Continuous Glucose Monitor tracings taken from 8 participants during 
the nocturnal period (12:00AM - 6:00AM), following the day of low activity 
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Figure Sc. Continuous Glucose Monitor tracings taken from 8 participants during 
the nocturnal period (12:00AM - 6:00AM), following individuals' hockey games 
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Figure 6. Mean nocturnal Blood Glucose concentration including bars of standard 
deviation recorded from midnight (00:00) to 6:00 AM (06:00) after participating in 
laboratory exercise, a low activity day, or a hockey game in the preceding day. 
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N=9 for lab exercise, N=9 for low activity, N=8 for game. 
Lab exercise night saw a BG drop of 1.7 mmol/L (range: 12.4±2.6 to 10.7±3.7 mmol/L), 
AUC 4143 mmol·L-1·min-1. Low activity night saw a BG drop of 3.0 mmol/L (range: 
11.3±5.3 to 8.3±2.7 mmol/L), AUC 3496 mmol·L-1·min-1. Game night saw a BG rise of 
0.7 mmol/L (range: 9.3±1.9 to 10.1±3.4 mmol/L), AUC 3563 mmol·L-1·min-1. 
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Figure 7. Continuous Glucose Monitor tracing taken from an individual 
experiencing nocturnal hypoglycemia following a hockey game, after being in 
relatively good control before sleep. 
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This individual had a pre-game meal along with an insulin bolus, 3 hours before their 
hockey game. Blood glucose plateaued for the duration of the hockey game, after which 
time the individual tested their glucose and consumed a post-game meal and insulin 
bolus. Post-game glucometer results indicated false hyperglycemia (BG: 12.9 mmol/L), 
which resulted in excess insulin being taken. Nocturnal hypoglycemia followed, lasting 
230 minutes. 
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Heart Rate Variability 
Thirty-minute post-exercise recordings were complete for 15 individuals (8 T1 Os, 7 
controls). Five individuals were not able to supply HRV in exercise recovery due to 
limitations in equipment availability. This included 2 individuals from the T1-a group and 
3 from the Ctrl-a group. As depicted in Figure 8, group analyses revealed that while 
SDNN, HF, and QTc were greater in the T1-a group than the ctrl-a group, the 
differences· were only slight and not significant (SDNN~ 82.62±45.57 vs 59.1"1 ±17 .80, 
p=0.22; HF: 43.00±18.58 vs 34.00±15.08 n.u., p=036; QTc: 432.18±8.35 vs 
425.66±23.18 ms, p=0.50) 
Nocturnal HRV recordings were complete for all individuals. This resulted in 20 
nocturnal recordings following the hockey-type laboratory exercise protocol, 20 after the 
low physical activity day, and 18 after the hockey game day. One individual had 
prolonged artifact during the night, which resulted in one hour being excluded from 
analysis. To match the recording length with other study participants, HRV analysis for 
this individual was extended by one hour. 
Of the nocturnal reports, 2nd and 3rd degree atrioventricular (AV) blocks were 
noted in 2 participants (5%), both whom were non-diabetic. This was in line with the 
findings of previous research on young elite athletes (99). Additionally, 2 individuals with 
T1 D had EKGs which revealed single ventricular and supraventricular contractions on 
all three recording nights, while another with T1 D revealed abnormal T-wave 
morphology in three leads, on all three nights. Heart rate pauses lasting greater than 1.9 
seconds were noted on 5 participants' EKGs and occurred between 02:00h and 05:00h. 
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One Ctrl-a individual had a high prevalence of heart pauses, with 15 pauses following 
the laboratory exercise, 28 pauses after the low physical activity day, and 7 pauses after 
a hockey game. All individuals with noted abnormalities were referred to their family 
doctor for follow-up. 
Prolonged QTc lasting 5 minutes or more on any one of the study nights was 
identified in twelve participants (half were from T1-a). Four of the twelve individuals 
·experienced prolonged QTc, lasting more than 10% of the night"(3 from T1-a, 1 from · 
Ctrl-a). Of these four individuals, the prolonged QTc was noted following both exercise 
days for one participant, and following all 3 days for the others. When considering all 
incidences of prolonged QTc, there was no relationship with BG level. Relationship 
between nocturnal hypoglycemia and HRV could only be studied in one individual and is 
shown in figure 9. In this individual, correlation between BG and QTc was -0.573 and 
significant at the p<0.0001 level. 
Nocturnal RR length was shorter after exercise took place in the preceding day, 
indicating that HR had not returned to baseline even hours after exercise had ended. 
Individuals' means from each night were combined across all participants, as there was 
no significant difference between T1-a and Ctrl-a RR values. Overall means from each 
night can be viewed in Figure 10. 
Heart rate variability measures did not differ between the T1-a and Ctrl-a groups 
on any of the nights. There was a trend toward slightly improved nocturnal HRV after a 
low activity day in both groups, compared to when highly intense exercise took place in 
the preceding day. The time domain measures SDNN, RMSSD, and pNN50 were all 
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significantly greater after the low activity day compared to either of the exercise days 
(p<0.05 in all cases). The low activity day also displayed benefits to the HRV profile as 
seen by the RR and QTc measures. RR length was significantly longer after a low 
activity day compared to the two exercise days (p<0.001), indicating a lower resting 
heart rate on the low activity night. Slight but significant QTc elongation was evident 
after the lab exercise compared to the low activity day (p<0.05). This trend was also 
presen_t between the hockey_ game and low activity night, however it did_ not reach 
significance (p=0.08). 
Individual data and group means for various HRV measures are located in tables 
4, 5, and 6. Figure 11 shows graphical representation of average nocturnal SDNN and 
RMSSD values for each night, and figure 14 shows average QTc length for each night. 
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Figure 8. Heart rate variability measures averaged for each individual, over 30 
minutes of exercise recovery. 
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"Exercise recovery" took place after the hockey-type lab exercise protocol in the T1-a 
(open circles) and Ctrl-a (filled circles). 
No significant differences were found between T1-a and Ctrl-a HRV in exercise 
recovery. 
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Figure 9. 6-hour tracing from a Continuous Glucose Monitor from an individual 
experiencing nocturnal hypoglycemia (<3.9 mmol/L), and QTc length averaged 
over 5-minute intervals, plotted on the right Y-axis. 
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QTc for much of the night preceding the incidental hypoglycemia was within a normal 
range (<440 ms), as indicated by + symbols. In this individual, only once hypoglycemia 
sets in, does QTc noticeably lengthen, indicated by X symbols. Correlation between BG 
and QTc on this night was significant, with an r value of -0.5727 (p<0.0001). 
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Figure 10. Median nocturnal heart rate with boxes to show the 1st and 3rd 
quartiles, and whiskers showing minimum and maximum values, following the 
hockey-type lab exercise, low activity, or game in the preceding day. 
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Nocturnal heart rate from individuals was significantly increased during sleep, after 
exercise took place in the preceding day (p<0.0005). Mean nocturnal HR after lab 
exercise, low activity, and a hockey game was 60 ± 8, 55 ± 6, and 60 ± 7 bpm, 
respectively. Values were 7-10 beats higher in females than males on each night 
(p<0.05), and no different between the t1-a and ctrl-a group (p=0.69). 
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Table 4. Individual and group mean RR and corrected QTc values from the 12am-
6am period following the hockey-type lab exercise protocol, low activity day, and 
hockey game. 
RR QTc 
Lab Exercise Low Activity Hockey Game Lab Exercise Low Activity Hockey Game 
Tl-a Ctr I-a Tl-a Ctrl-a Tl-a Ctrl-a Tl-a Ctrl-a Tl-a Ctrl-a Tl-a Ctrl-a 
1127.00 882.00 1174.69 912.53 1091.40 867.77 445.36 434.00 437.08 429.70 448.00 434.44 
908.63 827.58 975.90 946.48 871.46 846.58 419.46 441.26 414.61 446.85 412.54 437.74 
874.00 813.29 863.53 878.58 843.99 828.88 448.00 464.55 441.64 460.58 446.08 454.36 
967.21 1286.62 1048.07 1307.82 1003.18 1210.65 421.67 416.51 424.63 410.26 416.60 422.08 
992.00 H58.23 1088.92 1311.87 -- -- 428.00. 377.44 429.88 368.67 -- --
1080.03 1137.00 1138.48 1117.00 1111.89 1056.53 437.19 425.00 438.52 424.00 437.86 431.94 
1066.19 1044.30 1127.33 1160.59 1002.09 1045.00 407.91 423.52 407.64 424.63 410.86 426.00 
1060.62 935.86 1131.25 966.25 1103.92 891.32 407.30 412.84 406.50 413.03 420.97 422.89 
1036.92 1054.25 1032.00 1342.46 960.70 1113.21 409.58 430.61 417.00 401.04 411.42 397.29 
960.47 1040.81 1003.03 1024.07 963.39 913.47 434.75 415.95 423.27 403.56 439.17 419.36 
10011.a 1027.991 : tOs8i.ai·. 1096.76 994\67 974.82 '425.92 424.17 424.08 418.23 427.06 . 427.34 
±Sql.52 :tl66132' _;,.g4 .• o§J. · :ltl~7.05 :t96.94 ±135.24 : ±15.18 ±22.36 ±12.65 ±25.55 :U5'.S?_ ±15.51 
10'17 .65 ± 1_27 .62 . i 10'7'7'.~4 ±1~9\.38 984~75±114.60 425.04 ± 18.62 421.15 ± 19.85 427.20 ± is..06 
I II I I I I 
I 
' ' 
I 
P=0.0008* P<0.0008* P<0.05** P=0.08 
No significant differences existed between T1-a and Ctrl-a groups on any of the nights, 
when considering 6-hour average RR and QTc lengths. Similarly, no differences were 
noted in the nocturnal measures following the lab exercise compared to the hockey 
game. 
*When combining the 2 groups and comparing average values based on night, RR was 
significantly shorter on the two nights where exercise took place in the preceding day, 
indicating higher mean heart rate (p<0.0005 for both T-tests). 
**When combining the 2 groups and comparing average values based on night, QTc 
was significantly longer on the night following the hockey-type lab exercise protocol 
(p<0.05). Despite a greater mean difference between nocturnal QTc following low 
activity and the hockey game, significance was not reached due to the fewer number of 
participants (p=0.08). 
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Table 5. Individual and group mean HF/total and triangular index values from the 
12am-6am period following the hockey-type lab exercise protocol, low activity 
day, and hockey game. 
HF (n.u.), Triangular Index 
Lab Exercise Low Activity Hockey Game Lab Exercise Low Activity Hockey Game 
Tl-a Ctrl-a Tl-a Ctrl-a Tl-a Ctrl-a Tl-a Ctrl-a Tl-a Ctrl-a Tl-a Ctr I-a 
0.61 0.50 0.64 0.54 0.61 0.52 49.71 19.40 47.28 20.26 53.35 20.61 
0.42 0.43 0.25 0.57 0.34 0.48 22.54 22.76 24.59 27.82 18.43 19.24 
0.31 0.35 0.35 0.40 0.30 0.39 14.96 21.41 16.86 18.79 13.99 15.59 
0.45 0.50 0.55 0.52 0.43 0.36 25.95 35.30 37.43 53.41 32.30 27.28 
0.31 0.42 0.33 0.36 -- -- 17.93 40.16 19.65 40.76 -- --
0.62 0.22 0.68 0.31 0.70 0.24 58.99 12.22 44.49 10.84 59.86 25.34 
0.36 0.23 0.37 0.24 0.31 0.21 32.12 21.36 33.42 22.13 28.56 17.62 
0.59 0.45 0.44 0.44 0.49 0.44 51.42 18.12 22.07 26.10 32.37 25.28 
0.28 0.60 0.36 0.47 0.25 0.59 22.21 57.75 35.16 27.07 27.01 57.60 
0.28 0.44 0.39 0.49 0.39 0.36 33.02 23.37 28.50 49.24 28.64 24.50 
0.42 0.41 0.44 '0.43 0.43 0.40 32.89 27.68 30.94 29.64 32.72 25.89 
±0.~~ . _;o.~2 ±0.14 
.c tO._lJ~ ±0.15 ±0.12 ±15.36 ±13.42 ±10.37 ±13.79 ±14.93 ±12.53 
0.4'2±0.-13 0•43 ± O.llz 0.41 ±0.14 30.29 ± 14.29 3Q.29 ± 11.89 29.31 ± 13.83 
I II I . I 
' ' ' ' P=0.40 P=0.07 P=0.10 P=0.76 
No significant differences existed between T1-a and Ctrl-a groups on any of the nights, 
when considering 6-hour-averages of relative HF power and triangular index values. 
Furthermore, after combining the two groups, no significant differences were observed 
between nocturnal collections. 
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Table 6. Individual and group mean SDNN and pNN50 values from the 12am-6am 
period following the hockey-type lab exercise protocol, low activity day, and 
hockey game. 
SONN J pNNSO 
Lab Exercise Low Activity Hockey Game Lab Exercise Low Activity Hockey Game 
Tl-a Ctrl-a Tl-a Ctrl-a Tl-a Ctrl-a Tl-a Ctrl-a Tl-a Ctrl-a Tl-a Ctrl-a 
176.53 85.16 192.98 88.03 171.49 78.68 69.89 32.21 70.27 40.57 70.65 26.92 
100.06 89.74 131.66 114.99 85.08 85.23 31.98 15.05 44.82 45.97 1.14 22.05 
82.86 74.74 79.08 69.92 71.43 61.23 6.06 14.89 13.12 24.80 5.45 15.11 
129.99 176.64 155.41 195.70 152.94 139.87 41.61 63.52 58.94 66.51 41.83 43.41 
129.51 155.77 106.24 170.69 -- -- 19.89 65.03 10.08 64.30 -- --
193.94 95.31 175.88 101.37 204.99 143.39 69.81 13.74 70.86 11.61 71.90 32.71 
138.96 90.64 152.44 114.45 117.51 93.66 54.09 5.70 56.60 22.21 44.98 7.71 
149.84 108.43 156.31 109.72 129.06 105.98 52.05 22.42 40.42 28.48 49.74 22.92 
102.04 183.42 160.91 167.40 116.93 187.61 31.95 69.78 43.51 58.22 24.08 71.24 
134.49 129.77 121.45 175.78 121.46 95.91 27.89 42.05 43.82 52.12 43.90 15.32 
1sa.s2 188~96- 143 .. 24 1~0.81 130.10 110'.17 401.52 34.46 45.24 41.48'. 40.96 28.60 
±~4.16 ±391{91, ±33~9'1 ±itt2.8_6 :tt41.41 ±39.50 ±20.97 ±24.16 ±20.81 ±19'.01 :t72'.65 ±19.13 
126.39 ± 36.9~ u-1.o:z± 3s~15 120.14 ± 40.58 37.49 ± 22.24 43.36 ± 19.52 34.1'.8 ± 21.31 
I II T T II I 
I 
' ' ' P<0.04* P<0.04* P<0.03** P<0.02** 
No significant differences existed between T1-a and Ctrl-a groups on any of the nights, 
when considering 6-hour average SDNN and pNN50 values. Similarly, no differences 
were noted in the nocturnal measures following the lab exercise compared to the 
hockey game. 
*After combining the 2 groups and comparing average values based on night, SDNN 
was significantly lower on the two nights where exercise took place in the preceding 
day, indicating more favourable HRV on the low activity night (p<0.04 for both T-tests). 
**After combining the 2 groups and comparing average values based on night, pNN50 
was significantly higher on the night following a low activity day, indicating more 
favourable HRV in these elite athletes following a rested day (p<0.03 for both T-tests). 
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Figure 11. 6-hour nocturnal average of SDNN and RMSSD from 00:00-06:00 
following the lab exercise, low activity, and hockey game days. 
Average SDNN Average RMSSD 
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T1-a values are shown by open circles and Ctrl-a values are shown by closed circles. 
Group means are displayed by lines; broken line represents T1-a, solid line represents 
Ctrl-a. No significant difference was found between HRV between T1-a and Ctrl-a 
group. After calculating an overall mean value for each night, nocturnal SDNN and 
RMSSD were lower after the lab exercise and hockey game, compared to the low 
activity day (*p<0.04 for SDNN and .**p<0.02 for RMSSD). 
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Figure 12. Average 12:00-6:00AM corrected QT values from each participant, 
following each activity, with group means represented. 
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There was no difference in average nocturnal QTc length between athletes with or 
without diabetes, indicating that heart contractility is not disadvantaged in this 
population with type 1 diabetes. 
Mean nocturnal QTc was longer after the lab exercise compared to the low activity day 
(*p<0.05), but not between the game and low activity day (p=0.08). The lack of 
significance may be due to the fewer number of individuals who contributed HRV 
measures after a hockey game. 
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DISCUSSION 6 
Blood Glucose 
One of the most challenging aspects of managing T1 D is controlling blood glucose. 
While physical activity participation is recommended for individuals with T1 D and T2D, it 
further complicates the relationship between carbohydrate consumption and insulin 
injection in order to maintain balanced BG. Although recommendations are made for 
managing BG with physical activity participation, all physical activity is not the same. 
Different kinds of physical activity can have profoundly different effects on BG, as is 
demonstrated in this study. 
This study aimed to match work done in the laboratory to that done in a regular 
hockey game. Nonetheless, BG response for each type of exercise bout was different. 
While BG tended to decrease with the laboratory exercise, hockey had a seemingly 
opposite effect. The type of physical activity cannot solely account for this difference 
since food and insulin were not controlled in this study however it certainly presents a 
possible explanation. It seems that the psychological excitement and release of 
adrenalin associated with hockey games causes an increase in BG that is not seen with 
similar-intensity exercise in a controlled laboratory setting. This is particularly important 
because guidelines which offer BG management strategies are typically based on 
studies with exercise occurring in a laboratory setting, rather than in the field. In order to 
accurately guide individuals with T1 D in their glucose regulation during sports, efforts 
should be made to include studies performed in the field when designing activity-
specific guidelines. 
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IHE has been implicated in preventing the decreases in BG that are seen with 
steady-state, moderate-intensity exercise (83). Our study demonstrated a similar 
absolute BG decrease of 2-3 mmol/L. Compared to the laboratory physical activity, 
similar high intensity bouts were experienced with hockey play, yet most individuals 
experienced a rise in BG from the start to the end of their game. One individual 
experienced a drastic drop in BG with the hockey game which skewed the data and 
_made the mean incre~se less drastic. It is i~portant to note that ~his individual went in~o 
their hockey game at a BG of 17 .4 mmol/L and took an insulin bolus to correct for their 
high BG. This resulted in their BG falling to a more appropriate level of 11.2 mmol/L 
after their hockey game. An additional individual started their hockey game at a BG of 
22.1 mmol/L and saw their levels drop to 20.88 mmol/L. While this countered the 
general trend of BG increasing with hockey, it is natural and healthy to see a drop in BG 
at such hyperglycemic states. As such, this individual contributed to the number of 
individuals who did not see a BG rise with hockey, and also made the mean increase 
less drastic. 
Nocturnal BG was high in many participants, after all nights. The greatest 
prevalence of nocturnal hyperglycemia occurred following the hockey-type laboratory 
physical activity session. The drop in BG that many experienced from the laboratory 
exercise bout may have led to over-consumption of carbohydrate in the evening hours, 
and subsequent hyperglycemia with sleep. On the other hand, the low physical activity 
day and game day resulted in nocturnal BG values that were closest to the euglycemic 
range. While a seemingly positive effect of a low activity day, this was negated by the 
large 3 mM drop that occurred from midnight to 6:00 AM. Previous literature (100) 
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specifies that overnight BG change should be no more than 1.7 mM. The hockey game 
night was associated with the smallest change in BG, which may be a result of the work 
that individuals in this study have put into understanding their BG levels with hockey. 
While a lot of personal experimentation goes into perfecting BG management 
with sport in elite athletes, the poorer BG management after the non-hockey days 
suggest that BG trend familiarity may be activity-specific. For example, young hockey 
players with T1 D rnay work so hard at optimizing BG levels with hockey games that 
management is improved with that specific activity, but that activity alone. As 
demonstrated by AUC measurements and total BG change overnight, nocturnal BG 
management was improved following a hockey game, but not after similar IHE occurred 
in a controlled setting, or after a day in which no exercise took place. 
Unfortunately, one individual experienced a prolonged hypoglycemic episode 
following their hockey game (Figure 7). Upon further analysis of the CGM, it appeared 
that the individual's BG was coming down after their pre-game meal and insulin bolus, 
at which point their hockey game caused their BG to plateau for its duration. Following 
the hockey game, this individual's glucometer suggested that their BG had increased 5 
mM (to 12.9 mM) with the hockey game, and thus they took a correctional bolus to for 
the apparent hyperglycemia. Retrospective CGM analysis revealed a BG of 8 mmol/L; a 
euglycemic level which would not have provoked an insulin bolus. Hockey players with 
T1 D are accustomed to experiencing BG rises with hockey, and it was likely because of 
this familiar trend that the individual in this case did not question the accuracy of their 
meter. The false glucometer high may have been caused by remnants of glucose on the 
finger that their lancet pricked - a common error when taking glucometer readings. 
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While efforts are made to ensure safe and accurate glucometer readings are performed, 
it is important that individuals with T10 be mindful of the consequences of erroneous 
glucometer readings. Particularly with BG measurements made around the time of 
physical activity, duplicate readings may be ideal. 
Following the correction with a bolus of insulin, BG values decreased and led to 
the nocturnal hypoglycemic episode. Fortunately the hypoglycemia resolved· itself, but 
with its relationship to DIB, that is· not always the case. ·1n one review (71), the 
participation in exercise combined with over-insulinization before bed was documented 
in several cases of DIB. This brings our attention to the importance of ensuring that the 
correct amount of carbohydrate and insulin is consumed following strenuous physical 
activities such as a hockey game, in order to reduce nocturnal hypoglycemia. 
While this research was conducted on hockey players with T10, it can be 
generalized to other sports. Similar sports that include intermittent high-intensity 
exercise in adrenalin-rising games would be expected to bring about similar trends in 
BG. Examples may include lacrosse, soccer, and basketball. It is interesting to note 
however, that the rises in BG are not commonly reported in hockey practices. As such, 
it is important to engage in careful BG monitoring with practices and games, to establish 
effective regimens. If similar rises in BG are confirmed by other studies, T1 D guidelines 
may be modified to recommend the consumption of fewer pre-game carbohydrates, and 
to consume water during their games rather than sports beverages which contain 
glucose. In order to prevent nocturnal hypoglycemia, rises in BG that occur with games 
should be treated with patience. Patients should be aware that BG may naturally 
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decrease following the IHE, as glycogen stores are replaced. If hyperglycemia persists, 
corrective insulin can be taken in small amounts so that hypoglycemia does not ensue. 
Heart Rate Variability 
T1 D and ANS dysfunction are two health ailments that are certainly related, though this 
.complex relationship is one which needs to. be further elucidated, Previous research has 
been inconclusive as to the first onset of sub-clinical ANS disturbances in youth with 
T1 D. The impact of age, blood pressure, physical activity level, and BG control on HRV 
in T1 D is highly debated. However, puberty seems to be a critical period for the 
development of impaired ANS function. This study demonstrated that even after the 
onset of puberty, hindrances were not noted in highly-active, highly-trained youth with 
T1 D. This suggests that being physically fit may confer cardioprotective effects which 
delay the onset of ANS dysfunction in individuals with T1 D. 
It was interesting to note the high prevalence of prolonged QTc (>450 ms in 
boys, >460 ms in girls), occurring in 60% of the study participants. Contrary to other 
studies, prolonged QTc presented itself throughout the BG spectrum and was not more 
prevalent during hypoglycemia. While the onset of hypoglycemia did bring about 
prolonged QTc in one individual following their hockey game, prolonged QTc was 
similarly noted on another night in this individual, despite maintaining stable BG control 
between 7.9 and 9.4 mmol/L. An additional individual had prolonged QTc on all three 
nights without experiencing any hypoglycemia. On one evening, this particular 
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individual's BG was cycling from values as high as 12.9 to as low as 6.2 mmol/L, 
however they never fell within the hypo-or excessively hyperglycemic ranges. 
QTc lengthening was also not biased toward those with T1 D compared to those 
without. While the incidence of long QTc was just as high after a low physical activity 
day as a day where intense exercise took place, prolonged QTc has been linked to low 
potassium as a result of intense exercise. Therefore this study may emphasize the 
importance of electrolyte replacement post-exercise, particularly in those with T1 D 
whose diagnosis puts them at increased risk for nocturnal sudden death. This may not 
reduce QTc lengthening after low physical activity days, but it could positively impact 
HRV profile (in particular QTc) after intense exercise, thereby reducing risk of sudden 
death. 
This study highlighted the fact that HRV is not reduced in young elite athletes 
with T1 D, compared to their non-diabetic teammates. While many studies suggest that 
reduced HRV can be noted at the onset of T1 D diagnosis, many of them fail to mention 
the physical activity status of the participants. This study offers a more optimistic view 
for these individuals, if they are highly active or become highly trained athletes. Despite 
the positive impact chronic exercise seems to have on HRV of athletes with T1 D, it is 
interesting to note t~at most optimal HRV profiles were noted in all athletes after the 
low-activity day. This may very likely be a result of over-training in elite athletes, which 
results in reduced HRV due to fatigue (101 ). This research (101) suggested that HRV 
should be studied in high-level athletes in order to determine when the athlete is 
experiencing fatigue and should reduce training, or when the athlete is well-rested and 
can take on more rigorous training. In light of this, the slightly improved HRV that the 
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present study observed after a low active day may be a result of the rest day which 
allowed their bodies to rest and recover. Nonetheless, it seems most accurate to 
conclude that a single bout of intense physical activity does not acutely reduce HRV in 
elite athletes with T1 D, who do not possess disturbances in the autonomic nervous 
system. 
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LIMITATIONS & FUTURE DIRECTIONS 7 
The specific population targeted by this study prevented a large sample from being 
recruited and assessed. As a result, even though there were trends of increased HRV 
indices in those with T1 D compared to those without, the findings were not significant 
due to the large variability between individuals. It would be advantageous to include 
more individuals in this study, and have a 50% intake of females, matched on menstrual 
cycle phase. It will also be meaningful to complete assessment and analysis of age- and 
sex- matched non-active individuals with T1 D. 
Despite selecting a nocturnal period during sleep to assess HRV because of the 
risk of DIB in T1 D, this introduced several possible confounds. For one, the signal was 
non-stationary, as the participants may have been moving around in their sleep; This 
could have led to less-clear and therefore false reports of various spectral frequency 
bands. Sleep stages and breathing rate were not accounted for, which can also 
introduce confounds. Because the monitors were set up at home by participants or their 
parents, the EKG configuration was not set up identically for all participants. This may 
have resulted in false differences in TP, and power measures which were not 
comparable from different Holter recordings. If the situation allowed, it would be ideal to 
have the participants visit a sleep laboratory for HRV analysis following each day. This 
would allow a trained individual to set up the EKG on each participant, and to control for 
movement during sleep. A sleep laboratory would also allow for the use of a 12-lead 
EKG set up on the Holter monitor, instead of the 5-lead set up that was used by this 
study. 12-lead set ups allow for a more thorough picture of heart rate activity to be 
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formulated, therefore most QTc analyses are conducted exclusively on data from 12 or 
more leads. In this study, a simpler 5-lead set up was used to promote simplicity of 
Holter monitor set up for participants, and comfort while sleeping. While many studies 
on healthy individuals suggest that sleep is characterized by an increase in HF power 
which is less obvious in those with T1 D, this study did not assess HRV at rest, before 
sleep. If this study were repeated, it would be ideal to monitor HRV in an evening period 
"'.'Jhile lying in bed, wit~ paced breathing. 
As a result of losing at least partial CGM data for 2 individuals, nocturnal 
hypoglycemia may have been missed. Furthermore, prolonged QTc could not be 
correlated to BG values in these participants. It would have been ideal to re-do the 
study on the individuals who lost their CGM values, so that analyses could be 
completed. 
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Appendix A: Recruitment Poster 
Do you hove trouble managing your glucose 
levels during or after games? 
Are you interested in learning more about how 
hockey influences your body? 
In an area of many unknowns, we want to help. 
'Mlat we're studying: 1) glucose levels <Uing and after hockey games 
2) post-exercise heart rate variability 
What is required: Must visit an exercise lab et Yori< Universiyon 2 occasions 
' 
0 
I 
* Participants wil be fitted with a glucose monitor {Medtronic iPro2) and Polar heart 
rate monitor to wear for 1 week, including 1 hockey game 
* Lab VISit 1: maxinun aerobic threshold test {V02 max) on a treadmill 
*Lab VISit 2: 6'krftJte exercise bout on a stationary bike 
* Must wear a non-invasive Holter monitor on 3 ri~ to assess the effed of hockey 
& hockey-~ activity on glucose levels and heart rate variability. 
If intero:t.d, ploca:e contact Li:a at lmiadov<9yorku.ca, 416-736-2100 
ext 22324 
fl ~ Q ti ~ ~ ~ I ~ I 
' 
~ 
i i i t i i i 
' 
i x~~.~I! 
' I j 0 j t I i I I t I I I J J ~ t'•(d-HH THS POSSIBLE i 1 i i 1 
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Appendix C: Consent Forms 
Minor Assent Form 
Study Name: Assessing the impact of intermittent high-intensity exercise on subsequent glucose management and 
autonomic function in elite-level youth athletes with type 1 diabetes 
Researchers: Dr. Michael Riddell, Dr. Veronica Jamnik 
mriddell@yorku.ca, ronij@yorku.ca, 416-736-2100 ext 22324 
Lisa Miadovnik, MSc Candidate, Kinesiology & Health Science, York University, 
lmiadov@yorku.ca 
Purpose of the Research: This will be the first study completed and published on type 1 diabetic hockey players. 
Because of the unique glycemic response reported in hockey players, we want to see how this type of exercise 
impacts later glucose management. We also want to see how hockey-type exercise impacts overnight autonomic 
function. Autonomic function refers to how the nervous system functions and can be measured by looking at heart 
rate variability. A Holter monitor is used to assess heart rate variability, which is basically the variation in the time 
interval between heartbeats. Since a healthy nervous system constantly changes how it stimulates the heart, a healthy 
person will have high heart rate variability. Our overall goal is to determine the effects that hockey and hockey-type 
exercise have on your blood sugar management and heart rate variability afterwards. We also want to see if blood 
sugar levels impact heart rate variability. This research will be presented to graduate students and professors at a 
seminar held at York University. We also aim to have it published in an academic journal, and presented at various 
professional conferences on diabetes. 
What You Will Be Asked to Do in the Research: This study will require 2 trips to the Human Performance 
Laboratory at York University. All participants will complete an initial fitness assessment in the laboratory which 
will take roughly 1.5 hours. This assessment will include measurement of height, weight, skinfolds/body fat, and 2 
maximal exertion cardiorespiratory tests. On this visit, each participant will be required to complete a 30-second 
Wingate anaerobic cycling test, and a 15-20 minute aerobic (V02 max) test performed on a motorized treadmill. 
Participants will also be required to visit the lab on a 2nd occasion which will last 2.5-3 hours. During this visit, the 
participants will complete an exercise protocol on a cycle ergometer which mimics the work done by the legs during 
a hockey game. This protocol will involve 45 minutes of intermittent cycling, which will take gJace over a 60 minute 
time frame (to simulate a game). Participants will wear a polar heart rate strap, and a Fitmate V02 device which 
will continuously measure the amount of oxygen you're using- or how hard you're working. Following the 
completion of this protocol, all equipment will be removed and a Holter Monitor TM will be placed on the participant. 
This monitor will be worn for 30 minutes in exercise recovery, while lying down in a dark, quiet room. 
The Holter Monitor TM is a small electronic device, worn on the hip. Connected to it are 5 wires with gel pads that 
are stuck to the front of the chest cavity. These gel pads pick up electrical activity of the heart, and transmit the 
information to the monitor, where the information is recorded. This monitor is to be worn on 3 occasions, from 
12:00 AM or earlier, until 6:00 AM or later. One occasion will be after completing the lab exercise protocol as 
mentioned above. A second occasion will be after a hockey game, and a third occasion will be after a low-activity 
day. Individuals will be asked to record the activities they partake in on each of these 3 days. It is important that 
minimal physical activity is performed on the low-activity day. 
All of the above requirements apply to both participants with diabetes, and their control (non-diabetic) 
participants. All procedures listed above are non-invasive. 
Participants with diabetes will have the additional requirement of wearing a Medtronic iPro2, blinded continuous 
glucose monitor (CGM), for the 3 days when they assess their nocturnal heart rate variability. Scheduling will be 
designed so that all 3 data collection nights (ie after the hockey game, after the lab exercise protocol, and after the 
low-activity day) occur within a 5-day span. While wearing the CGM, participants will also be asked to manually 
check their blood sugar using their own glucose monitoring device at least once every 9 hours, and record all 
carbohydrate consumption and insulin administrations on the provided sheets. 
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Risks and Discomforts: Because this strenuous exercise is known to induce hyperglycemia during exercise, 
participants may suffer post-exercise hypoglycemia afterward. Participants will receive coaching on how to reduce 
the incidence of hypoglycemia by exercise specialists such as Dr. Riddell - for example, reduce onboard insulin to 
zero during exercise, restrict insulin after exercise, and monitor blood glucose levels closely after exercise so that if 
levels start to drop, glucose can be consumed. Participants are also exposed to the typical risk of injury that is 
associated with exercise, including fatigue, lightheadedness, loss of consciousness, abnormal blood pressure, chest 
discomfort, leg gramps, nausea, and in rare cases, heart rhythm disturbances or heart attacks. Because all 
participants are elite athletes who are accustomed to intense exericse, the likelihood of experiencing the above side 
effects are quite small. Additionally, exercise will be supervised by qualified professionals to limit the risks to the 
participants, and a consent form will be read and signed by the dependent's parent or guardian prior to initiating the 
study. PAR-Q+ and if necessary, ePAR-meclX evaluations will also be completed prior to exercise to insure 
participants are all eligible to partake in exercise, and understand the associated risks. 
Benefits of the Research and Benefits to You: You will have the opportunity to participate in unique fitness 
testing procedures that are common to many elite and national-level athletes. You will also have access to your 
CGM data upon study completion, to .observe the impact of hockey on your blood sugar management. 
Voluntary Participation: Your participation in the study is completely voluntary and you may choose to stop 
participating at any time. Your decision not to volunteer will not influence the nature of the relationship you may 
have with the researchers or study staff, or the nature of your relationship with York University either now, or in the 
future. 
Withdrawal from the Study: You can stop participating in the study at any time, for any reason, if you so decide. 
Your decision to stop participating, or to refuse to answer particular questions, will not affect your relationship with 
the researchers, York University, or any other group associated with this project. If you choose to withdraw from the 
study, all associated data collected will be immediately destroyed if you choose. 
Confidentiality: All information you supply during the research will be held in confidence and unless you 
specifically indicate your consent, your name will not appear in any report or publication of the research. Data will 
be collected via hand-written notes, and converted into electronic documents where possible. All collected 
information will be coded to preserve your anonymity. Your data will be safely stored in a password-protected 
computer in a locked facility and only research staff will have access to this information. Confidentiality will be 
provided to the fullest extent possible by law. Collected data will be kept for a maximum of 5 years, after which 
time it will be destroyed. 
Questions About the Research? If you have questions about the research in general or about your role in the 
study, please feel free to contact Lisa Miadovnik or the Graduate Supervisor - Dr. Michael Riddell either by 
telephone (listed above) or by e-mail (mriddell@yorku.ca). This research has received approval by the Human 
Participants Review Sub-Committee, York University's Ethics Review Board and conforms to the standards of the 
Canadian Tri-Council Research Ethics guidelines. If you have any questions about this process or about your rights 
as a participant in the study, please contact the Sr. Manager & Policy Advisor for the Office of Research Ethics, 5th 
Floor, York Research Tower, York University (telephone 416-736-5914 or e-mail ore@yorku.ca). 
Legal Rights and Signatures: 
I consent to participate in "Assessing the impact of intermittent high-intensity exercise 
on subsequent glucose management and autonomic function in elite-level youth with type 1 diabetes" conducted by 
Lisa Miadovnik, Supervised by Dr. Michael Riddell & Dr. Veronica Jamnik. I have understood the nature of this 
project and wish to participate. I am not waiving any of my legal rights by signing this form. My signature below 
indicates my consent. 
Signature Date 
Participant 
Signature Date 
Principal Investigator 
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Parental Consent Form 
Study Name: Assessing the impact of intermittent high-intensity exercise on subsequent glucose management and 
autonomic function in elite-level youth athletes with type 1 diabetes 
Researchers: Dr. Michael Riddell, Dr. Veronica Jamnik 
mriddell@yorku.ca, ronij@yorku.ca, 416-736-2100 ext 22324 
Lisa Miadovnik, MSc Candidate, Kinesiology & Health Science, York University, 
lmiadov@yorku.ca 
Purpose of the Research: This research aims to be the first-ever study completed and published on type 1 diabetic 
hockey players. Given the unique glycemic response reported in hockey players, we aim to assess the impact of this 
type of exercise on subsequent glucose management. We also aim to assess the acute effects of hockey-type exercise 
on nocturnal autonomic function. Autonomic function refers to how the nervous system functions and can be 
measured by looking at heart rate variability. A Holter monitor is used to assess heart rate variability, which is 
basically the variation in the time interval. between heartbeats. Since a-healthy nervous system constantly changes 
how it stimulates the heart, a healthy person will have high heart rate variability. Our overall purpose is to determine 
the nocturnal effects of hockey and hockey-type exercise on blood sugar management and heart rate variability, and 
to determine whether the two markers are correlated. This research will be presented to peers at a graduate seminar 
held at York University. We also aim to have it published in a scholarly journal, and presented at various 
professional conferences on diabetes. All participants will remain anonymous. 
What You Will Be Asked to Do in the Research: This study will require 2 trips to the Human Performance 
Laboratory at York University. All participants will require an initial fitness assessment in the laboratory which will 
take roughly 1.5 hours. This assessment will include measurement of height, weight, skinfolds/body fat, and 2 
maximal exertion cardiorespiratory tests. On this visit, each participant will be required to complete a 30-second 
Wingate anaerobic cycling test, and a 15-20 minute aerobic (V02 max) test performed on a motorized treadmill. 
Participants will also be required to visit the lab on a 2nd occasion which will last 2.5-3 hours. During this visit, the 
participants will complete an exercise protocol on a cycle ergometer which mimics the work done by the legs during 
a hockey game. This protocol will involve 45 minutes of intermittent cycling, which will take place over a 60 minute 
time frame (to simulate a game). Participants will be fitted with a polar heart rate strap, and a Fitmate TM V02 device 
which will continually assess the volume of oxygen utilized by the exercising individual. Following the completion 
of this protocol, individuals will be asked to lay down for 30 minutes to assess heart rate variability in recovery. This 
monitor will be worn for 30 minutes in exercise recovery, while lying down in a dark, quiet room. 
The Holter Monitor™ is a small electronic device, worn on the hip. Connected to it are 5 wires with gel pads that 
are stuck to the front of the chest cavity. These gel pads pick up electrical activity of the heart, and transmit the 
information to the monitor, where the information is recorded. This monitor is to be worn on 3 occasions, from 
12:00 AM or earlier, until 6:00 AM or later. One occasion will be after completing the lab exercise protocol as 
mentioned above. A second occasion will be after a hockey game, and a third occasion will be after a low-activity 
day. Individuals will be asked to record the activities they partake in, on each of these 3 days. It is important that 
minimal physical activity is performed on the low-activity day. 
All of the above requirements apply to both participants with diabetes, and their control (non-diabetic) 
participants. All procedures listed above are non-invasive. 
Participants with diabetes will have the additional requirement of wearing a Medtronic iPro2, blinded continuous 
glucose monitor (CGM), for the 3 days when they assess their nocturnal heart rate variability. As such, scheduling 
will be designed such that all 3 data collection nights (ie after the hockey game, after the lab exercise protocol, and 
after the low-activity day) occur within a 5-day span. While wearing the CGM, participants will also be asked to 
manually check their blood sugar using their own glucose monitoring device at least once every 9 hours, and record 
all carbohydrate consumption and insulin administrations on the provided sheets. 
Risks and Discomforts: Because exercise of this intensity is known to induce hyperglycemia during exercise, 
participants may suffer post-exercise hypoglycemia afterward. Participants will receive coaching on how to reduce 
the incidence of hypoglycemia by exercise specialists such as Dr. Riddell - for example, reduce onboard insulin to 
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zero during exercise, restrict insulin after exercise, and monitor blood glucose levels closely after exercise so that if 
levels start to drop, glucose can be consumed. Participants are also exposed to the typical risk of injury that is 
associated with exercise, including fatigue, episodes of transient lightheadedness, loss of consciousness, abnormal 
blood pressure, chest discomfort, leg gramps, nausea, and in rare cases, heart rhythm disturbances or heart attacks. 
Because all participants are elite athletes who are accustomed to intense exericse, the likelihood of experiencing the 
above side effects are quite small. Additionally, exercise will be supervised by qualified professionals to reduce 
potential risks to the participants, and a consent form will be read and signed by the dependent's parent or guardian 
prior to initiating the study. PAR-Q+ and ifnecessary, ePAR-medX evaluations will also be completed prior to 
exercise to insure participants are all eligible to partake in exercise, and understand the associated risks. 
Benefits of the Research and Benefits to You: Participants will have the opportunity to experience unique fitness 
testing procedures that are common to many elite and national-level athletes. They will also have access to their 
CGM data upon study completion,. to observe the impact of hockey on their blood sugar management. This 
information will be available as a result of their participation in this study. 
Voluntary .Participation: Participation.in the study is completely voluntary and individuals may choose to stop 
participating at any time. The decision not to volunteer will not influence the nature of the ongoing relationship you 
may have with the researchers or study staff, or the nature of your relationship with York University either now, or 
in the future. 
Withdrawal from the Study: You or your dependent can stop participating in the study at any time, for any 
reason, if you so decide. Your decision to stop participating, or to refuse to answer particular questions, will not 
affect your relationship with the researchers, York University, or any other group associated with this project. In the 
event you withdraw from the study, all associated data collected will be immediately destroyed if you choose. 
Confidentiality: All information supplied during the research will be held in confidence and unless consent is 
specifically indicated, names will not appear in any report or publication of the research. Data will be collected via 
hand-written notes, and converted into electronic documents where possible. All collected information will be coded 
to preserve your anonymity. Data will be safely stored in a password-protected computer in a locked facility and 
only research staff will have access to this information. Confidentiality will be provided to the fullest extent possible 
by law. Collected data will be kept for a maximum of 5 years, after which time it will be destroyed. 
Questions About the Research? If you have questions about the research in general or about your role in the 
study, please feel free to contact Lisa Miadovnik or the Graduate Supervisor - Dr. Michael Riddell either by 
telephone (listed above) or by e-mail (mriddell@yorku.ca). This research has received approval by the Human 
Participants Review Sub-Committee, York University's Ethics Review Board and conforms to the standards of the 
Canadian Tri-Council Research Ethics guidelines. If you have any questions about this process, or about your rights 
as a participant in the study, please contact the Sr. Manager & Policy Advisor for the Office of Research Ethics, 5th 
Floor, York Research Tower, York University (telephone 416-736-5914 or e-mail ore@yorku.ca). 
Legal Rights and Signatures: 
----------- provide my consent for my dependent to participate in "Assessing the impact of 
intermittent high-intensity exercise on subsequent glucose management and autonomic function in elite-level youth 
with type 1 diabetes" conducted by Lisa Miadovnik, Supervised by Dr. Michael Riddell & Dr. Veronica Jamnik. I 
have understood the nature of this project and wish my dependent to participate. I am not waiving any of my legal 
rights by signing this form. My signature below indicates my consent. 
Signature Date 
Participant 
Signature Date 
Principal Investigator 
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Informed Consent Form 
Study Name: Assessing the impact of intermittent high-intensity exercise on subsequent glucose management and 
autonomic function in elite-level youth athletes with type 1 diabetes 
Researchers: Dr. Michael Riddell, Dr. Veronica Jamnik 
mriddell@yorku.ca, ronij@yorku.ca, 416-736-2100 ext 22324 
Lisa Miadovnik, MSc Candidate, Kinesiology & Health Science, York University, 
lmiadov@yorku.ca 
Purpose of the Research: This research aims to be the first-ever study completed and published on type 1 diabetic 
hockey players. Given the unique glycemic response reported in hockey players, we aim to assess the impact of this 
type of exercise on subsequent glucose management. We also aim to assess the acute effects of hockey-type exercise 
on nocturnal autonomic function. Autonomic function refers to how the nervous system functions and can be 
measured by looking at heart rate variability. A Holter monitor is used to assess heart rate variability, which is 
basically the variation in the time interval between heartbeats. Since a healthy nervous system constantly changes 
how it stimulates the heart, a healthy person will have high heart rate variability. Our overall purpose is to determine 
the nocturnal effects of hockey and hockey-type exercise on blood sugar management and heart rate variability, and 
to determine whether the two markers are correlated. This research will be presented to peers at a graduate seminar 
held at York University. We also aim to have it published in a scholarly journal, and presented at various 
professional conferences on diabetes. All participants will remain anonymous. 
What You Will Be Asked to Do in the Research: This study will require 2 trips to the Human Performance 
Laboratory at York University. All participants will require an initial fitness assessment in the laboratory which will 
take roughly 1.5 hours. This assessment will include measurement of height, weight, skinfolds/body fat, and 2 
maximal exertion cardiorespiratory tests. On this visit, each participant will be required to complete a 30-second 
Wingate anaerobic cycling test, and a 15-20 minute aerobic (V02 max) test performed on a motorized treadmill. 
Participants will also be required to visit the lab on a 2nd occasion which will last 2.5-3 hours. During this visit, the 
participants will complete an exercise protocol on a cycle ergometer which mimics the work done by the legs during 
a hockey game. This protocol will involve 45 minutes of intermittent cycling, which will take place over a 60 minute 
time frame (to simulate a game). Participants will be fitted with a polar heart rate strap, and a Fitmate ™ V02 device 
which will continually assess the volume of oxygen utilized by the exercising individual. Following the completion 
of this protocol, individuals will be asked to lay down for 30 minutes to assess heart rate variability in recovery. This 
monitor will be worn for 30 minutes in exercise recovery, while lying down in a dark, quiet room. 
The Holter Monitor TM is a small electronic device, worn on the hip. Connected to it are 5 wires with gel pads that 
are stuck to the front of the chest cavity. These gel pads pick up electrical activity of the heart, and transmit the 
information to the monitor, where the information is recorded. This monitor is to be worn on 3 occasions, from 
12:00 AM or earlier, until 6:00 AM or later. One occasion will be after completing the lab exercise protocol as 
mentioned above. A second occasion will be after a hockey game, and a third occasion will be after a low-activity 
day. Individuals will be asked to record the activities they partake in, on each of these 3 days. It is important that 
minimal physical activity is performed on the low-activity day. 
All of the above requirements apply to both participants with diabetes, and their control (non-diabetic) 
participants. All procedures listed above are non-invasive. 
Participants with diabetes will have the additional requirement of wearing a Medtronic iPro2, blinded continuous 
glucose monitor (CGM), for the 3 days when they assess their nocturnal heart rate variability. As such, scheduling 
will be designed such that all 3 data collection nights (ie after the hockey game, after the lab exercise protocol, and 
after the low-activity day) occur within a 5-day span. While wearing the CGM, participants will also be asked to 
manually check their blood sugar using their own glucose monitoring device at least once every 9 hours, and record 
all carbohydrate consumption and insulin administrations on the provided sheets. 
· Risks and Discomforts: Because exercise of this intensity is known to induce hyperglycemia during exercise, 
participants may suffer post-exercise hypoglycemia afterward. Participants will receive coaching on how to reduce 
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the incidence of hypoglycemia by exercise specialists such as Dr. Riddell - for example, reduce onboard insulin to 
zero during exercise, restrict insulin after exercise, and monitor blood glucose levels closely after exercise so that if 
levels start to ·drop, glucose can be consumed. Participants are also exposed to the typical risk of injury that is 
associated with exercise, including fatigue, episodes of transient lightheadedness, loss of consciousness, abnormal 
blood pressure, chest discomfort, leg gramps, nausea, and in rare cases, heart rhythm disturbances or heart attacks. 
Because all participants are elite athletes who are accustomed to intense exericse, the likelihood of experiencing the 
above side effects are quite small. Additionally, exercise will be supervised by qualified professionals to reduce 
potential risks to the participants, and a consent form will be read and signed by the dependent's parent or guardian 
prior to initiating the study. PAR-Q+ and if necessary, ePAR-medX evaluations will also be completed prior to 
exercise to insure participants are all eligible to partake in exercise, and understand the associated risks. 
Benefits of the Research and Benefits to You: Participants will have the opportunity to experience unique fitness 
testing procedures that are common to many elite and national-level athletes. They will also have access to their 
CGM data upon study completion, to observe the impact of hockey on their blood sugar management. This 
information will be available as a result of their participation in this study. 
Voluntary Participation: Participation in the study is completely voluntary and individuals may choose to stop 
participating at any time. The decision not to volunteer will not influence the nature of the ongoing relationship you 
may have with the researchers or study staff, or the nature of your relationship with York University either now, or 
in the future. 
Withdrawal from the Study: You can stop participating in the study at any time, for any reason, if you so decide. 
Your decision to stop participating, or to refuse to answer particular questions, will not affect your relationship with 
the researchers, York University, or any other group associated with this project. In the event you withdraw from the 
study, all associated data collected will be immediately destroyed if you choose. 
Confidentiality: All information you supply during the research will be held in confidence and unless you 
specifically indicate your consent, your name will not appear in any report or publication of the research. Data will 
be collected via hand-written notes, and converted into electronic documents where possible. All collected 
information will be coded to preserve your anonymity. Your data will be safely stored in a password-protected 
computer in a locked facility and only research staff will have access to this information. Confidentiality will be 
provided to the fullest extent possible by law. Collected data will be kept for a maximum of 5 years, after which 
time it will be destroyed. 
Questions About the Research? If you have questions about the research in general or about your role in the 
study, please feel free to contact Lisa Miadovnik or the Graduate Supervisor - Dr. Michael Riddell either by 
telephone (listed above) or by e-mail (mriddell@yorku.ca). This research has received approval by the Human 
Participants Review Sub-Committee, York University's Ethics Review Board and conforms to the standards of the 
Canadian Tri-Council Research Ethics guidelines. If you have any questions about this process, or about your rights 
as a participant in the study, please contact the Sr. Manager & Policy Advisor for the Office of Research Ethics, 5th 
Floor, York Research Tower, York University (telephone 416-736-5914 or e-mail ore@yorku.ca). 
Legal Rights and Signatures: 
I provide my consent to participate in "Assessing the impact of intermittent high-
intensity exercise on subsequent glucose management and autonomic function in elite-level youth with type 1 
diabetes" conducted by Lisa Miadovnik, Supervised by Dr. Michael Riddell & Dr. Veronica Jamnik. I have 
understood the nature of this project and wish to participate. I am not waiving any of my legal rights by signing this 
form. My signature below indicates my consent. 
Signature Date 
Participant 
Signature Date 
Principal Investigator 
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Appendix D: Holter Guide 
DR200 Hook-Up Guide for Holter 
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DR200 Quick-Start Guide for Holter 
GENERAL SETTINGS: 
Contnst • Ad;usts LCD screen contrast 
TO START RECORDER FOR HOLTER 
Step 1 - Insert formatted SO Card and battery into recorder. 
Step 2 • Screen wil display "OR2000iE" and ·NonhEast Monit~· information.• 
Press ENTER lo continue 10 ma~ menu. Erase memory if prompted to do so. 
Step 3 • If desired. adjust Settings by using arTOWS • T and • • 10 move the cursor 
and the ENTER button to select. Use arrows to navigate to General Settings 
menu and to adjust entries. Press ENTER to select and retum to menu. 
Step 4 ·From main menu go to Nevi Patient screen to verify or enter Patient 10. 
At least one character must be eniered for Patient ID. 
Step 5 • Use arrows and ENTER IO input 10 and press EVENT when finished. (Hold dolm ENTER button 
to baclcspace.) Reoorder \viii now start automaticily after 10 minutes or by pressing EVENT 
button for 3 seoonds. ECG signa~ and quality will appear on seceen. 
Step 6 ·To remow card after recording. gentty push inward to releaJe 
Nner pull card out of slol. as rt ~Y damage the recorder 
*Note: If screen dispJays a 15 second countdown, you wilt need to interrupt 
by pressing ENTER, T, •, and EVENT buttons, in that order. 
MESSAGES: 
Lud Loose • EnaNesJOisables "lead Loose· error message 
Event Marter. Denotes event location on ECG 
LEAD LOOSE - Occurs when the patient is not hooked 119 or if there is a problem with 
the hook up. The problem may be vnm an electrode. a lead. or the eaNe that connects 
lhe leads to the recorder. The messa~e viii oontinue 10 lash for about 10 seconds a~er 
oorrected. \Vhen corrected. the ECG. then Time-of.day wil appear on the screen. If you 
choose. you can tum this error message olf via the main menu. Key mode • "Quief turns olf key beeping. "Delayed" prevents accidental 
events by requiring patient to hold button down for several seoonds to 
record an event 
Rec Type • S\'tilch be!Wffn Holter. Event or Both recocding modes. 
Menu Lock • Locks settings on the recorder 
To lock recorder enter ·211· 
To unlod: the recocder enter ·151· 
Language • Choose from multiple languages 
Hi Res • Enabk!OisaNe high resolutJOn reoording (Holler only.) 
Diary • Enable/Dwble patient text diaries. 
Battery LOW or FAILURE- Put in new battery before starting recorder. 
Erase memory YE SINO - If the SD card has been used fOf a previous patient. you \'till 
need to erue now, If the card should not be erased as ii has ECG data that you do not 
want to lose. you ml need to remove it and put in a new formatted SO card. 
SO Card errors • SD Cards must be forrniitted using your LX Holter software. Refer 
IO your Operator's Manual fOf details on SO Card errors and hor1 to format and correct. 
v1V1V1.nemon.com Copyright 2008. 2012 Northeast Monitoring, Inc. NEMM020 • Rev-E ·English· August 2012 
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Appendix E: Activity Log 
Participant Name: 
Date Activity, Duration, Intensity 
Hockey/Lab Exercise/Low Activity 
Hockey/Lab Exercise/Low Activity 
Hockey/Lab Exercise/Low Activity 
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Participant: (name) 
On the attached sheet, please record activities performed each day. These can include things like 
walking to school, biking, activities on lunch break, walking around a mall, etc. Include 
psychological stressors if they apply, especially if they occur near bed time (try to avoid these!). 
This sheet does not have to be overly specific or completely accurate - just do your best. 
Estimate the duration of each activity and rank the intensity from 1-5 (1 being a slow walk, 5 
being an intense game or activity). 
Please ensure you are "low active" on the low active day- (include date here). 
If possible, try to match your physical activities during the day on your hockey game day to the 
physical activities you performed on the day you visited the ·lab for the biking session (date). For 
example, if you were fairly inactive during the day before coming in for the hockey-type lab 
exercise, aim for the same on your game day. 
Holter Monitor: 
Instructions are included in your kit. Ensure the correct wires are attached to the correct gel pads 
(and not on the opposite side of the body). For the nights you wear the monitor, please aim to 
sleep from 11 pm at the latest, until at least 6am. 
If the time on the holter monitor is different from the actual time, please record both times on the 
· attached sheet, when you start the monitor recording. 
Record the time you get into bed or the time you think you will fall asleep at. 
Record the time you wake up at, and so long as it is past 6am, you can turn off and remove the 
monitor. 
To turn off the monitor, simply pull the battery out. 
Throw the battery in the garbage so it is not accidentally reused the following night. 
Remove the memory card so it does not get written over during the next use. 
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Appendix F: Hockey-type laboratory exercise protocol 
Name: Date: Period: 1 2 3 
Pre-Weight: Post-Weight: Resistance: 
Shift On Ice ~ - whi§''e -£1&v Off Ice Bench 
1 0:00 20-20-40 1:20 
RPM 
HR/V02 
t. I 
2 3:10 20 - 30 - 20 - 30 ~ 15 5:05 
I RPM 
I 
H'RYV02 I 
--- - "-- ' -
3 6:00 30-20-10 7:00 
RPM I 
H'RJV02 
i 
- -- -
·-
I. 
4 10:10 10-20-40 11:20 
RPM 
H!R/V02 
5 12:10 30-20-20 13:20 
RPM 
1-
I 
HR/V02 
! 
_J .• 
6 15:40 10-20-10 16:20 
RPM 
HR/V02 
i 
: ,, 
7 17:20 20-40-20-40-20-10-10 20:00 
RPM 
I 
HR/V02 
L 
Blood Sugar check!!! 
Pre: Period 1 end: Period 2 end: Post: 
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Appendix G: Additional Recruitment 
Because there was no HRV difference between the athletes with T10 compared to 
those without, we cannot ascertain that our measures worked properly unless we recruit 
a group of non-active individuals with T10 and see slightly diminished HRV as is 
supported by the literature. While this was not originally a part of this thesis project, it 
has been added in hopes of securing a publication once complete. 
In addition to the participating hockey players with and without T10, a group of non-
athletes with T10 is being recruited ("T1-n"). These individuals are age-matched to the 
hockey-playing participants, and selected randomly based on being self-described as 
"inactive." Identical exclusion criteria were followed for this group as for the hockey-
playing participants with T10. For participation in the study, these individuals are 
required to wear a Medtronic iPro2 blinded CGM and wear a Holter monitor on two 
nights. The initial visit for these individuals includes insertion of the CGM as well as the 
collection of the same anthropometric measurements as taken on the hockey playing 
group. On this initial visit, individuals are required to have a safe and stable BG level of 
5-15 mmol/L prior to completing the aerobic fitness assessment. For this group of 
individuals, aerobic fitness is assessed by a maximal V02 test, conducted in the same 
manner as mentioned previously. No Wingate tests will be conducted on this group. 
Following completion of the V02 max test, individuals lay supine in a quiet, dark 
room while wearing the Holter monitor for 30 minutes. These individuals also wear the 
Holter monitors for the nocturnal collection after their V02 max test which was 
considered an "exercise day," and after a typical low activity day where no exercise was 
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performed. The HRV recordings after a low activity day in this group were to function as 
a reference group for the recordings of the elite hockey players. 
Currently, 3 indiv.iduals of this additional group have been included and their data 
analyzed. This includes one boy and two girls. Mean age was 16 ± 1, mean V02max 
was 38.38 ± 4.4 ml 0 2·kg-1 ·min-1. While these individuals did not complete the same 
exercise protocol as the hockey players did, their HRV was instead measured following 
their maximal V02 test. This group was also monitored after a ·typical low-activity day, 
and wore CGMs for the duration of the study. Their values have been super-imposed 
onto the earlier figures to show their placement with respect to the two athlete groups. 
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Heart rate variability measures averaged for each individual, over 30 minutes of 
exercise recovery, with an emphasis on the non-athlete population (T1-n), 
represented by asterisks. 
HRV in exercise recovery 
0 T1-a 
e Ctrl-a 
* T1-n 
200 500 -- - T1-a avg 
- Ctrl-aavg 
Cl) 0 
:::s 150 0 ni • > 0 ~~ 450 -I LL (") :c 0 CD" 100 -9~- :::s "C cc 
c: .+ 
C'G 
-yo-;- =r 
z 0 -
z $ 
• 
400 ~ 
c 50 -
"' •Je • 
0 350 
SDNN (ms) HF (nu) QTc 
HRV indices 
Left y-axis references SDNN and HF plots, right y-axis references QTc plots. 
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6-hour nocturnal average of SDNN and RMSSD from 00:00-0S:OOh following the 
lab exercise, low activity, and hockey game days, with values for the T1-n group 
added where applicable. 
Average SDNN Average RMSSD 0 T1-a 
• * :rl-a 11-n 
250 
---
T1-a avg 
0 - Ctrl-aavg u; 200 0 g 0 eo• •o • 0 Oo o._ 
.0 0 
• 0 •oooo • o. o • • 0 150 • "C ~o-0..0 --~---c 
* • o••e* --0°0-0 • 
••• o 
0 • • 0 (.) 100 o_.o. • .oo-1.0-- 0 Q) •• •10• -:..e"*"o __ -0-aer•-~ •*•o o*• •• oe o ~~o .o • o~• i 50 * .,. 0 •001* 
*. * 
0 
Lab Ex Low Act Game Lab Ex Low Act Game 
T1-a values are shown by open circles and Ctrl-a values are shown by closed circles. 
Group means are displayed by lines; broken line represents T1-a, solid line represents 
Ctrl-a. Values from several tested non-active youth with T1 D (T1-n) are included in 
asterisks. No significant difference was found between HRV between T1-a and Ctrl-a 
group. After calculating an overall mean value for each night, nocturnal SDNN and 
RMSSD were lower after the lab exercise and hockey game, compared to the low 
activity day. 
All non-active individuals with T1 D (t1-n) had SDNN and RMSSD values that were 
below the T1-a means, indicating worsened HRV, however more individuals are needed 
to confirm this apparent trend. 
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Average 12:00-6:00AM corrected QT values from each participant, following each 
activity, with group means represented, and T1-n values included 
Average QTc 
0 T1-a 
• Ctrl-a 500 
* 
T1-n 
- - - • T1 -a avg 
·-!. 450 • • -- Ctrl-a ·avg o!o* * •oo •o .* tn 8*•·0 oo oo .. • "'CS _!~..ge-c - ... -:c:•- •"-al 0 
•;po• 0 000 CJ Q) •o 0 • • 
• !a 400 •• • 
:! 
• 
• 
350 
Lab Ex Low Act Game 
Activity undertaken in preceding day 
There was no difference in average nocturnal QTc length between athletes with or 
without diabetes, however there seems to be an increase in QTc length in non-athletes 
with T1 D. More individuals in the T1-n group are needed to confirm this trend. 
Mean nocturnal QTc was longer after the lab exercise compared to the low activity day 
(p<0.05), but not between the game and low activity day (p=0.08). The lack of 
significance may be due to the fewer number of individuals who contributed HRV 
measures after a hockey game. 
QTc length seems to be longer in the T1-n group, but this needs to be verified with more 
participants. 
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